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1. Abbreviations 
 
 
AAV  adeno-associated virus 
Ag  antigen 
APC  antigen presenting cell or allophycocyanin  
 AIRE  auto-immune-regulator protein 
 Bdnf  brain-derived neurotrophic factor 
 blastn  nucleotide blast 
blastp  protein blast 
BM  bone marrow 
bp bp  base pairs 
CD  cluster of differentiation  
CMV  cytomegalovirus 
CFA  complete Freund’s adjuvant  
CFSE  carboxyfluorescein-diacetate-succinimidylester 
CLP  common lymphoid progenitor  
CMP  common myeloid progenitor  
cTECs  cortical thymic epithelial cells 
CTL  cytotoxic T lymphocyte 
dNTP  desoxyribonucleotidtriphosphate 
DC  dendritic cell 
DC-STAMP  dendritic cell-specific transmembrane protein 
DLI  donor lymphocyte infusion 
E. coli  Escherichia coli 
eGFP  enhanced green fluorescent protein 
FACS  fluorescence activated cell sorter 
FBS  fetal bovine serum  
Fc, FcR  fragment crystallizable, Fc-Receptor 
FITC  fluoresceinisothiocyanate 
forw  forward 
Foxp3  transcription factor forkhead box P3 
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5-FU  5-Fluoro-Uracil 
GVHD  graft versus host disease  
GVL  graft versus leukemia 
 HLA  human leukocyte antigen 
HSC  hematopoietic stem cells 
HSV  herpes simplex vírus 
HSVgB  herpes simplex vírus glycoprotein B  
i.e.  id est, from Latin that is. 
Ig  immunoglobulin 
IKDC  interferon-producing killer dendritic cell  
IL  interleukin 
IFN-I  interferon type I (alfa and beta) 
IFN-α/β  interferon alfa/beta 
IFN-γ  interferon-gama 
IL2RG  γ-chain of the interleukin-2 receptor 
i.p. / i.v.  intraperitoneal / intravenous  
kb  kilobase 
LTR  long terminal repeat 
NK cell  natural killer cell 
µg  microgram 
µl  microliter 
MHC  major histocompatibility complex 
MFI  mean fluorescent intensity 
MNC  mononuclear cells 
MOI  multiplicity of infection  
mTECs  medullary thymic epithelial cells 
OD  optical density 
O/N  over night 
ORF  open reading frame 
OVA  ovalbumin 
pBS  plasmid Blue Script 
PBS  buffered saline solution 
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PCR  polymerase chain reaction 
pDC  plasmacytoid dendritic cell 
PE  phycoerythrin 
PerCP  peridinin-Chlophyll-a Protein 
qPCR  quantitative PCR 
rev  reverse 
RIP  rat insulin promoter 
RNA  ribonucleic acid 
RT  room temperature 
SA  streptavidin  
s.c.  subcutaneous  
SCID  severe combined immunodeficiency 
SFFV  Spleen-focus forming virus  
SIN  self-inactivating 
SIINFEKL  OVA257-264 
SSIEFARL  HSVgB498-505 
Ta  annealing temperature  
TCR  T cell receptor 
TGF-β  transforming growth factor beta 
TLR  toll like receptor 
Tm  melting temperature 
TNF-α  tumor necrosis factor alfa 
trOVA  transmembrane OVA 
Treg  regulatory T cell  
TSA  tissue-specific antigen 
TU  transducing units 
UTR  untranslated region 
UV  ultraviolet  
vs.  versus 
v/v  volume per volume 
X-SCID   X-linked form of severe combined immunodeficiency 
   
 10 
WPRE WPRE  Woodchuck hepatitis virus posttranscriptional regulatory 
  element 
w/v  weight per volume 
w/w  weight per weight 
   
 11 
 
2. Abstract 
 
Dendritic cells (DC) are the most powerful antigen presenting cells (APCs) of the 
immune system. Since DCs can induce both tolerance and immune responses, there is 
an increased interest in understanding the biology of DCs for basic research and clinical 
applications. Different DC subpopulations have been described and several attempts 
have been made trying to correlate these DC subsets with different functions. However, 
the difficulties to manipulate DC ex vivo or in vitro without changing their original 
phenotypic and functional characteristics are major obstacles in DC-research. In this 
study, we developed a novel lentiviral vector allowing DC-selective transgene 
expression after hematopoietic stem cell transduction. We show that this gene-therapy 
approach yields DC-selective expression, which is maintained long-term. When we 
analyzed the in vivo functionality of this method, we were able to show induction of 
antigen-specific CD4+ and CD8+ T cell tolerance to the virally encoded transgene 
expressed by DCs. This tolerogenic state was not reverted even after immunization and 
was sufficient to avoid development of autoimmune disease. In addition, our preliminary 
data in vitro show that this system also targets human DCs. Together, this data 
supports the delivery of transgenes specifically to DCs using viral vectors as a 
promising tool in gene therapy. 
 
 
Zusammenfassung 
 
Dendritische Zellen (DZ) sind die besten antigenpräsentierenden Zellen des 
Immunsystems. Da sie sowohl Toleranz wie auch Immunantworten induzieren können, 
ist es von großem Interesse die Biologie der DZ für Grundlagenforschung und klinische 
Anwendungen zu verstehen. Es wurden verschiedene DZ Subpopulationen 
beschrieben und etliche Versuche unternommen diese DZ Subtypen mit den einzelnen 
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Funktionen in Zusammenhang zu bringen. Die Manipulation der DZ ex vivo oder in vitro 
ohne den ursprünglichen Phänotyp und funktionelle Charakteristiken dabei zu 
verändern stellt jedoch ein großes Hindernis dar. In dieser Studie haben wir einen 
neuen lentiviralen Vektor entwickelt, der Expression von Transgenen nach der 
Transduktion hämatopoetischer Stammzellen selektiv in DZ ermöglicht. Wir zeigen, 
dass dieser Gentherapie-Ansatz zu DZ-selektiver Expression führt, welche langfristig 
erhalten bleibt. Bei der funktionellen Analyse dieser Methode in vivo konnten wir zeigen, 
dass in CD4- und CD8-positiven T-Zellen antigenspezifische Toleranz gegen das in DZ 
exprimierte und viral kodierte Transgen induziert wird. Die Toleranz konnte selbst durch 
Immunisierung nicht aufgehoben werden und war ausreichend um Autoimmunität zu 
verhindern. Zudem weisen vorläufige Ergebnisse in vitro darauf hin, dass dieses 
System auch in humanen DZ funktionieren kann. Lentivirale Vektoren dazu zu nutzen 
Transgene spezifisch in dendritische Zellen einzuführen, könnte ein vielversprechendes 
Hilfsmittel in der Gentherapie sein. 
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3. Introduction 
 
 
3.1 A brief introduction to immunology 
 
3.1.1 Innate and adaptive immunology 
 
The immune system has been classified into a more simple “innate” 
and into a more developed and complex “adaptive” (or acquired) immune system. The 
innate immune responses are present in both invertebrates and vertebrates, as well as 
in plants, and are the first line of defense of an organism. In contrast, the adaptive 
response is present only in vertebrates and involves more sophisticated mechanisms of 
defense. 
 
 
3.1.2.1 The innate immune system 
 
The innate immune system is crucial in the first hours and days after 
exposure to a new pathogen. Single bacteria for example, with an exponential rate of 
duplication, can produce around 20 million of progeny in a single day. Therefore, the 
innate immunity does not rely on pathogen-specific recognition, but rather on 
recognition of common patterns. The principal components of the innate immune 
system are: physical barriers, phagocytic cells, natural killer (NK) cells, complement 
system and cytokines. 
 
 
3.1.2.2 The adaptive immune system 
 
The adaptive system is highly specific for each pathogen. It can generate 
long lasting protection, so called immunological memory, that responds more vigorously 
and faster to a repeated exposure with the same pathogen. This principal is exploited 
by vaccination. The adaptive immune system is able to recognize and react to a 
universe of microbial and non-microbial substances and any molecule capable of 
eliciting an adaptive immune response is referred to as an “antigen” (Ag). There are 
basically two types of adaptive immune responses: cellular and humoral. 
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Although classified as innate and adaptive, both components of the immune 
system form an integrated system of host defense with numerous cells and molecules 
functioning cooperatively (Fearon and Locksley 1996). For example, dendritic cells 
(DCs) as part of the innate system recognize and phagocytose pathogens and, 
subsequently, as part of the adaptive system, they process and present the respective 
pathogen-derived antigens to other cells of the immune system. It is equally important 
to note that besides the aim of both systems to sense the presence of “non-self” 
patterns and antigens (or the presence of anomalous antigens when considering 
cancer), both systems are able to react against “self” tissues, which can lead to a 
process of autoimmunity. To avoid such responses to self molecules it is of cardinal 
importance that the immune system is always under surveillance to guarantee “self 
tolerance”. 
 
 
3.1.2 Antigen presentation 
 
Activated T cells proliferate and differentiate into effector cells only when 
antigen is displayed on the surface of antigen presenting cells (APCs). This occurs 
because T cells only recognize fragments of proteins that have been processed by 
APCs into peptides. These peptide fragments are then presented on the surface of the 
APC on so called “major histocompatibility complex” (MHC) molecules. T cells 
recognize such MHC-antigen complexes through their T cell receptor (TCR). There are 
two main types of MHC gene products, called class I MHC (MHC-I) and class II MHC 
(MHC-II) molecules, which present different pools of protein Ag. Intracellular (or 
cytosolic) antigens are presented by the MHC-I (present in all nucleated cells) to CD8+ 
cytotoxic T lymphocytes (CTL), while extracellular antigens that have been endocytosed 
are presented by MHC-II (found only in professional APCs, such as DCs, monocytes 
and B cells) to CD4+ helper T lymphocytes. There is also a mechanism called “cross 
presentation” that is restricted to DCs, in which extracellular antigens are presented by 
the MHC-I to CD8+ T cells (Bevan 1976; Bevan 2006).  
Under normal conditions, self-proteins are presented constantly by MHC 
molecules. However, self-proteins can be also recognized by T cells leading to 
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autoimmunity. To avoid self-reactivity several mechanisms have evolved to establish 
self-tolerance. 
 
3.2 Tolerance 
 
Tolerance means inability to respond to a certain antigen. This 
characteristic is essential to avoid destruction of self tissues and subsequent 
autoimmunity. At least two mechanisms control the “education” of the immune system: 
central and peripheral tolerance.  
 
 
3.2.1 Central tolerance 
 
Central Tolerance is induced at the primary sites of lymphocyte 
development: thymus for T cells and bone marrow for B cells. The main process 
responsible for T cell central tolerance is clonal deletion, in which T cells with high 
affinity for self-antigens die due to apoptosis. But there are other processes of tolerance 
induction in the thymus that do not involve removal but the generation of regulatory T 
cells; this process is called “non-deletional tolerance”. Although the second process is 
much less understood than the first, its importance in avoiding auto-reactivity and 
preventing autoimmunity has become clear in the last few years.  
 
 
3.2.1.1 Deletional tolerance 
 
T lymphocytes originate from a common hematopoietic stem cell (HSC) 
progenitor. Developing T cells in the thymus are called “thymocytes”. In the cortical 
region of the thymus, cortical thymic epithelial cells (cTECs) present different Ags to the 
thymocytes and those expressing low avidity TCR binding to self-antigen/MHC 
complexes survive, a process called “positive selection” (von Boehmer 1994). These 
cells migrate to the medulla, where DCs and medullary thymic epithelial cells (mTECs) 
present several different tissue-specific antigens (TSAs) to the T cells. Those T cells 
that recognize self-antigen/MHC complexes with high avidity are deleted by apoptosis, 
a process called “negative selection”.  
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The expression of TSAs in the thymus depends, at least in part, on the 
autoimmune regulator protein (AIRE), and such TSA expression seems to be restricted 
to TECs (Derbinski, Schulte et al. 2001). AIRE is a transcriptional regulator controling 
the expression of tissue-specific genes. AIRE-deficiency results in severe autoimmunity 
in both humans and mice (Anderson, Venanzi et al. 2002; Ramsey, Winqvist et al. 
2002). Although AIRE and TSAs are absent or expressed only at low levels in DCs, 
these cells pick up the antigens expressed by the TECs and present them to T cells. 
Therefore, DCs play an important role in central tolerance, being the most important 
cells able to delete auto-reactive CD4+ T cells in the thymus (Gallegos and Bevan 
2004). 
 
3.2.1.2 Non-deletional tolerance 
 
While it is accepted that central tolerance is mediated mainly by negative 
selection or clonal deletion in the thymus (Starr, Jameson et al. 2003), several studies 
showed that some of the self-reactive T cells undergo a process called non-deletional 
central tolerance. During this process, self-reactive T cells become anergic or give rise 
to regulatory T cells [Tregs; (Sakaguchi, Fukuma et al. 1985; Ramsdell and Fowlkes 
1990; Sakaguchi 2004; Fontenot and Rudensky 2005)], initially called 
immunosuppressive T cells (Modigliani, Thomas-Vaslin et al. 1995). It is believed that 
CD4+CD25+ Tregs are a distinct lineage of mature T cells and that cTECs alone are 
sufficient for their development (Bensinger, Bandeira et al. 2001). About 10% of the 
peripheral repertoire of CD4+ T cells are CD25+ and display suppressive function. For 
example, “scurfy” mice, which present a spontaneous mutation in the forkhead box 
transcription factor P3 (FOXP3- known to be present in Tregs), suffer from severe 
autoimmunity (Fontenot, Gavin et al. 2003; Khattri, Cox et al. 2003). Although Treg cells 
arise in the thymus, their suppressive function is seen mainly in the periphery 
contributing to peripheral tolerance. 
 
3.2.2 Peripheral tolerance 
 
Central tolerance is a very efficient but not entirely sufficient mechanism to 
eliminate all self-reactive lymphocytes, as not all TSA present in an organism are 
   
 17 
expressed in the thymus (Mathis and Benoist 2004). The mechanisms responsible for 
peripheral tolerance are: (i) functional inactivation, called anergy; (ii) apoptotic cell 
death, called deletion; and (iii) suppression of lymphocyte activation by Tregs. 
 
 
3.2.2.1 Anergy 
 
When T cells recognize Ags presented in absence of co-stimulation (such 
as B7), they are incapable of responding to the antigen, even if later the antigen is 
presented by a competent (or activated) APC. This state of non-responsiveness is 
called “anergy”. Anergy can be induced artificially, for example by administrating Ag 
without inflammatory signals. Anergy may also be induced if the T cell recognizes Ag in 
the context of inhibitory molecules such as PD-1 or CTLA-4. However, the regulation of 
such active tolerization is poorly understood, as these negative regulators are 
expressed and even upregulated also throughout productive immune responses 
(Walker and Abbas 2002).  
 
 
3.2.2.2 Apoptosis 
 
Repeated stimulation of T lymphocytes by persistent Ags results in death of 
activated cells by apoptosis. In CD4+ T cells repeated activation leads to the expression 
of two molecules, a death-inducing receptor called Fas and its ligand, FasL. This leads 
to activation of intracellular proteases, called caspases, causing cell death. It is believed 
that this kind of apoptosis is responsible for the elimination of T cells specific for 
abundant peripheral self-antigens (Siegel, Chan et al. 2000). The same pathway of 
apoptosis is involved in the elimination of self-reactive B cells, but seems not to be 
involved in apoptosis of CD8+ T cells. Mice with defects in the expression of Fas or 
FasL, and humans with mutations in Fas develop autoimmune diseases. 
 
 
3.2.2.3 Suppression by Tregs 
 
Tregs express a TCR able to recognize self-antigens with the difference 
that instead of being activated to generate autoimmunity, they inhibit effector T cells to 
maintain self-tolerance. The mechanism of action of Tregs is still not well established, 
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but it is known that secretion of immuno-supressive cytokines such as IL-10 and 
transforming growth factor-ß (TGF-ß) are involved (Shevach 2002). 
 
 
3.3 Dendritic cells 
 
DCs are specialized in capturing, processing and presenting Ags to T cells. 
There are many distinct DC subtypes with different localization and function in the 
immune system and most of these subpopulations have a short lifespan. Therefore, 
they need to be continuously renewed (Kamath, Henri et al. 2002). Although DCs have 
received a lot of attention from immunologists since their discovery, DC development, 
differentiation and their exact role in immune response vs. tolerance is still a very 
difficult and controversial subject in the field. 
 
 
3.3.1 Dendritic cell function 
 
DCs are among the most central components of the immune system, being 
the main professional APCs and contributing to both innate and adaptive immunity. 
They play a critical role in sensing pathogens, and several independent studies have 
shown their role in the interaction between the two immunological arms, regulating the 
strength, quality and persistence of Ag-specific adaptive immune responses (Shortman, 
2002). DCs can be found in primary and secondary lymphoid organs, as well as in 
almost every peripheral tissue. Within the thymus, DCs play an important role in 
thymocyte negative selection and central tolerance induction. In the periphery DCs are 
able to pick up Ags and migrate to the lymphoid organs to present the processed Ags to 
other cells of the immune system, inducing immune responses or tolerance. A simplified 
view is that signals received through receptors such as toll like receptors (TLRs), 
cytokine receptors and chemokine receptors, lead DCs towards a maturation process 
that enables them to induce T lymphocytes proliferation and immune response 
(Villadangos and Schnorrer 2007). On the other hand, in the absence of such signals, 
DCs remain in an immature state, inducing deletion or anergy of self-reactive T cells. It 
is through these mechanisms that DCs are thought to mantain peripheral tolerance 
(Banchereau and Steinman 1998; Dhodapkar and Steinman 2002). However, the 
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concept that mature DCs always promote immunity has been questioned, since even in 
this state they can induce tolerance (Albert, Jegathesan et al. 2001; Sporri and Reis e 
Sousa 2005; Reis e Sousa 2006).  
 
 
3.3.2 Dendritic cell sub-populations 
 
A large variety of DCs have been described and their proportion can vary 
accordingly with the different organs and tissues (Table 1). In mice, one can divide 
lymphoid tissue resident DCs into three major populations according to molecular 
markers, function and cytokine production: CD8-, CD8+ and plasmacytoid DCs. CD8-
CD11b+ DCs can be further classified in CD4+ and CD4- (double negative) DCs. CD8+ 
DCs are the only cells able to cross-present Ags on MHC-I molecules (den Haan, Lehar 
et al. 2000; Pooley, Heath et al. 2001; Heath, Belz et al. 2004). Plasmacytoid DCs 
(pDCs) are distinguished from the other subtypes by their expression of the CD45 
isoform B220, and are characterized by their potent ability to produce type I interferon 
(IFN-I) after viral infection (Asselin-Paturel, Boonstra et al. 2001; Liu 2005). Some 
immunologists classify pDCs as a DC precursor (together with monocytes), as after 
inflammatory stimuli they may develop some of the antigen-processing and antigen-
presentation properties characteristic to the conventional DCs (Shortman and Naik 
2007). It is important to notice that other DC types have been described in the literature 
during the last few years. Examples include the interferon-producing killer dendritic cell 
[IKDC; (Taieb, 2006)] and the CD19+ pDCs (Munn, Sharma et al. 2004). However, as 
they are present in the organism only under specific circumstances and in lower 
numbers, they are not considered further here. For an overview of the most important 
murine DC population cell markers see table 2.  
 
 
 
DC sub-
population 
Thymus  Spleen Lymph 
nodes 
Bone 
marrow 
CD8+ DCs ++ + + + 
CD8- DCs + ++ + + 
pDCs + + + ++ 
 
Table 1: Distribution of the murine DC sub-populations. DC, dendritic cell; pDC, plasmacytoid 
dendritic cell; +, present; ++, primary sub-type.  
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DC sub-
population 
Markers  
CD8+ DCs CD11c+, CD8+, CD205+, CD11b-, CD4- 
CD8- DCs CD11c+, CD11b+, CD8-, CD4+/-,  
pDCs CD11c+/low, B220+, CD11b-, PDCA+, Gr-1+, MHC-IIlow,  
 
Table 2: Markers that identify the different murine DC sub-populations. DC, dendritic cell; pDC, 
plasmacytoid dendritic cell;+, present; -, absent; low, low expression 
 
 
3.3.3 Dendritic cell origin 
 
Although extensively investigated, the origin of the different DC sub-
populations is still controversial. As all other blood cells, DCs have their ultimate origin 
in a hematopoietic stem cell (HSC) progenitor. One of the earliest steps of 
hematopoietic differentiation is to a common myeloid progenitor (CMP) or to a common 
lymphoid progenitor (CLP) (Akashi, 2000; Kondo, 1997). Already at this early stage, it is 
still not known at which point the DC subtypes diverge. For a long time it was believed 
that all DCs were derived from myeloid origin, since they have several similarities with 
macrophages and can even be differentiated from monocytes. Only after a series of 
several studies it was finally shown that CLP and CMP can give rise to both 
“conventional” and “lymphoid” DCs (Manz, 2001; Wu, 2001; Traver, 2000). The current 
view is that most of the DCs present in the peripheral lymphoid tissues are from myeloid 
origin and that many thymic DCs derive from an early T-lineage precursor. In 
accordance with this idea, it was shown that around half of the DCs found in the 
thymus, but only a small number of DCs residing in the spleen and lymph nodes, have 
immunoglobulin heavy-chain gene D-J rearrangements (Corcoran, Ferrero et al. 2003). 
Interestingly, about half of all pDCs, independent on the tissue where they are found, 
have such IgH D-J rearrangements (Corcoran, Ferrero et al. 2003; Shigematsu, Reizis 
et al. 2004). Because of these findings, DC subtype commitment seems to be dictated 
downstream of the early lymphoid or myeloid progenitors. Recently, a common bone 
marrow precursor of DCs and macrophages was isolated (Fogg, Sibon et al. 2006). 
This precursor has been shown to have the capacity to generate CD8- and CD8+ DCs, 
but not pDCs. These findings indicate that the pDC pathway branches off before this 
common macrophage/DC precursor, but it still remains to be determined whether this 
precursor is the only route of DC development. While a precursor able to give rise to 
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CD8- and CD8+ DCs but not pDCs has been described, there is no identification of a 
pDC precursor unable to produce CD8- and CD8+ DCs. The current model for pDC 
development in spleen and lymph nodes suggests a bone marrow progenitor, but this 
still remains to be determined. 
 
 
3.4 Autoimmunity 
 
 The immune system possesses the important function of protecting the 
host against infectious diseases and tumors, but in the event of failure of self-tolerance, 
the immune responses can be redirected against autologous antigens, leading to the 
development of autoimmune diseases. How self-tolerance fails and self-reactive 
lymphocytes are activated are fundamental issues in autoimmunity and likely the basis 
for understanding mechanisms of tolerance. The knowledge of autoimmune diseases 
cause and development has increased greatly in the last two decades, mainly because 
of the development of a variety of animal models and the identification of genes that 
might be involved in and/or cause predisposition to a particular disease. Nevertheless, 
the etiology of most autoimmune diseases remains obscure and understanding these 
disorders is a major challenge in immunology. Autoimmunity is an important cause of 
disease in humans, representing, in developed countries, the third major cause of 
morbidity and mortality after cancer and atherosclerosis (Chatenoud 2006). The current 
therapeutic approach is essentially anti-inflammatory and/or immunossupressive 
therapy, which are not specific to the antigens involved in the pathogenesis. These 
therapies lead to global suppression of the immune system and as consequence, 
increase the risk of infection and carcinogenesis, as well as other serious side effects 
such as osteoporosis. Moreover, such broad immunosuppression is only of transient 
therapeutic benefit. These are the reasons for the growing attention towards new 
biological agents and methods, including immuno and gene therapy, which present a 
great potential for rescuing antigen-specific tolerance. 
 
 
3.5 Immunotherapy 
 
Immunotherapy is the treatment of a disease with therapeutic agents, as for 
example antibodies, cytokines or (modified) cells of the immune system that promote or 
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inhibit immune responses. Immunotherapy has primarily been applied to treat several 
different types of cancer. One example of immunotherapy to treat autoimmune diseases 
or avoid transplant rejection is the use of proteins, such as interferons (IFNs) and 
several different cytokines, and the use of monoclonal antibodies against leukocyte 
specific antigens. Examples of such antibodies include anti-CD3 (Herold, Hagopian et 
al. 2002; Belghith, Bluestone et al. 2003; Chatenoud 2003; Trucco 2005), anti-CD40 
ligand alone or in combination with anti-CTLA-4 (Larsen, Elwood et al. 1996; Kirk, 
Harlan et al. 1997; Abbas 1999; Kirk, Burkly et al. 1999), anti-CD52 (Keating, Flinn et al. 
2002; Cohen and Nagler 2004), anti-CD4 (Moreland, Pratt et al. 1995; Choy, Schantz et 
al. 1998; Schulze-Koops and Lipsky 2000) and anti-TNF (Feldmann 2002). The 
consequence of this approach is generalized immunosuppression and other associated 
risks, since not only the auto-reactive lymphocytes are targeted. Moreover, cytokines 
and antibodies are expensive and have a short half-live, necessitating frequent 
administration. Furthermore, when the treatment stops the disease may rebound (van 
der Meide, de Labie et al. 1998). One potential alternative in achieving tolerance by 
eliminating only the pathogenic cells includes gene therapy. For example, DCs can be 
genetically modified with the objective to rescue self-tolerance leaving the other 
functions of the immune system unperturbed. 
 
 
 
3.5.1 Gene therapy 
 
Gene therapy comprises the delivery of new genetic material through 
different vectors into the cells of an individual for therapeutic purposes. In basic 
research, the same methodology can be used with investigatory objectives. To date, 
more then 3000 patients have already been treated with gene therapy worldwide 
(American Society of Gene Therapy, 2007). Several children with SCID have been 
treated with this methodology, where a retroviral vector was used to deliver a functional 
copy a defective gene in some HSC, which reconstituted the lymphoid system and 
cured the immunodeficiency (Cavazzana-Calvo, Hacein-Bey et al. 2000; Aiuti 2002; 
Gaspar, Parsley et al. 2004). Unfortunately, some of the children with the X-linked form 
of the disease (X-SCID) were later diagnosed with T-cell leukemia, considered to be a 
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consequece of the activation of the oncogene LMO2 as a result of retrovirus vector 
integration (Hacein-Bey-Abina, Von Kalle et al. 2003). Although no similar effects were 
found in children with another kind of SCID, this result raised serious concerns about 
the safety of the technique. The syndrome X-SCID is caused by faulty expression of the 
γ-chain of the interleukin-2 receptor (IL2RG) and gene therapy is used to restore 
IL2RG. Recently, it was shown in a murine model of X-SCID that the gene IL2RG itself 
can contribute to the development of T cell lymphoma and not the vector insertion in the 
genome (Woods, Bottero et al. 2006). However, the validity of this observation has 
been questioned concerning its extrapolation to humans (Pike-Overzet, 2006; Thrasher, 
2006). While the safety of gene therapy is still controversial and the development of 
improved therapeutic viral vectors is of fundamental importance, gene therapy still 
reflects an important tool in the treatment of diseases that cannot be treated by 
standard therapies or for which treatment causes severe side-effects. 
 
 
3.5.1.1 Commonly used vectors in gene therapy 
 
Efficient gene delivery is central to the success of gene therapy. Non-
immunogenic vectors are required because otherwise the cells transfected or tranduced 
with these vectors, and consequently their beneficial effect, are destroyed. Besides 
DNA, which can be delivered to cells either naked or complexed with liposomes, viral 
vectors are preferable vehicles as they have several advantages, such as intrinsic 
mechanisms for cell entry (DNA needs transfection techniques like electroporation or 
gene gun), integration into the host genome and long-term expression. Viral vectors 
commonly used in gene therapy include those derived from adenovirus, adeno-
associated virus (AAV), herpes simplex virus (HSV), retrovirus and lentivirus (for 
features of the main vectors used in gene therapy see table 3). Lentivirus is part of the 
retrovirus family, but with the aim of simplicity, commonly in gene therapy the term 
lentivirus is used as an independent virus type. As the vectors derived from retroviruses 
and lentiviruses are the only vectors that mediate DNA insertion into the host genome, 
and the aim of this work was to modify HSCs permanently so that their progeny would 
still present the transgene, the following background information and methodology will 
be restricted to these two vectors. 
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Vector Vector 
genome 
Transgene 
capacity 
Immu
no- 
genici
-ty 
Genomic 
integration 
Duration of 
expression 
Advanta
-ges 
Disadvanta-
ges 
Naked 
DNA 
DNA Unlimited Low No Short term Easy, 
fast and 
cheap to 
produce; 
support 
large 
transge 
-nes 
Lacks intrinsic 
mechanisms 
for cell entry; 
short term 
expression 
Adeno-
virus 
DNA 30 Kb High No 6 weeks Highly 
stable; 
support 
large 
transge-
nes; can 
be produ 
-ced at 
high 
titers 
Does not infect 
lymphocytes; 
more than 50% 
of humans 
have pre-
existing 
antibodies 
Adeno-
associa
-ted 
virus 
DNA 4.5 Kb low possible Long term Infect 
qiescent 
cells; 
site 
specific 
integra 
-tion in 
the host 
genome 
Low transgene 
capacity; low 
rate of 
integration in 
the host 
genome 
Herpes 
simplex 
virus 
DNA 50 Kb High No At least 6 
months 
Support 
large 
trans 
-genes; 
infect 
neuronal 
cells 
Induces 
cellular toxicity 
and 
inflammation; 
time 
consuming 
production 
Retro-
virus 
RNA 7-8 Kb Low Yes For the life 
of the cell 
Integra 
-tion in 
the host 
genome 
Can cause 
insertional 
effects; small 
transgene 
capacity; does 
not infect 
quiescent cells 
Lenti-
virus 
RNA 7-8 Kb Low Yes For the life 
of the cell 
Integra-
tion in 
the host 
genome; 
Infect 
qiescent 
cells; 
can be 
produ 
-ced at 
high 
titers 
 
Can cause 
insertional 
effects; small 
transgene 
capacity 
            
           Table 3: Features of the vectors used in gene therapy. Modified from Chernajovsky, 2004. 
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3.5.1.2 Retroviral and lentiviral vectors 
 
3.5.1.2.1 Retrovirus 
 
Retroviruses are enveloped viruses containing a single stranded RNA 
molecule as a genome. Following infection, the viral genome is reverse transcribed into 
double stranded DNA, which integrates into the host genome and can express viral 
proteins (Fig. 1, top). The viral genome is approximately 10 Kb, containing three genes: 
gag, coding for core proteins; pol, coding for reverse transcriptase; and env, coding for 
the viral envelope protein. At each end of the genome are long terminal repeats (LTRs) 
which include promoter/enhancer regions and sequences involved in genomic 
integration. In addition, there are sequences required for packaging the viral RNA (Ψ or 
psi) and RNA splice sites in the env gene. 
 
 
 
 
 
Figure 1. Schematic representation of a retrovirus (MoMLV) and a retroviral vector. (a) Wild type 
retrovirus contains genes encoding viral elements. (b) Some of the genes present in the retrovirus are 
replaced with cDNA encoding gene of interest, giving rise to the retroviral vector. LTR, long terminal 
repeat; MoMLV, Moloney murine leukaemia virus; WPRE, woodchuck hepatitis virus post-transcriptional 
regulatory element. 
 
 
Standard retroviral vectors are mostly based on Moloney murine leukaemia 
virus (MoMLV), which have the viral genes (gag, pol and env) replaced with the 
transgene of interest (Fig.1). As these viral genes are essential for virus production, 
they are expressed on plasmids in the packaging cell line. Transgene expression can 
be driven by the promoter/enhancer region in the 5´LTR or by alternative viral or cellular 
promoters. Though transgene expression is usually adequate, prolonged expression is 
difficult to mantein because the viral promoters tend to be inactivated. To avoid this 
silencing mechanism the use of host cell promoters has been a valuable approach. The 
use of cell specific promoters has other advantages as well, as it allows the expression 
of the transgene to be restricted to target cells or tissues of choice and at physiological 
levels. The cell-specific transcriptional targeting can be problematic since the viral 
promoter/enhancer present in the LTR interferes with the activity and regulation of cis-
a 
b 
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acting elements inserted in the virus backbone between the two LTRs (Emerman, 1984; 
Emerman 1986). To overcome this problem the use of self inactivating (SIN) retro- and 
lentiviral vectors has become a popular tool in gene therapy. SIN vectors lack the 
regulatory elements present in the U3 region of the 3´LTR of the viral RNA genome and 
after the process of reverse transcription to DNA and integration into the host genome, 
the internal promoter is the only one able to give rise to transcripts (fig 2; Yu, 1986; Yee, 
1987). 
 
 
Figure 2. Schematic representation of reverse transcription of a retroviral genome. (a) The 
genomic RNA of the retrovirus (yellow) is packed in the virion with a retrovirus-specific cellular tRNA 
(blue) hybridized to its PBS. This tRNA works as a primer that gives rise to the process of transcription of 
the viral RNA into DNA through the enzyme reverse transcriptase. RNaseH digests the RNA strand in a 
DNA-RNA hybrid. The entire process consists in serial events of reverse transcription, RNA digestion and 
“jump”/anneling to complementary sequences. The process yields a double strand DNA with identical 
a 
b 
   
 27 
LTRs at each end. (b) The same process of reverse transcription occurs when the genomic RNA is 
deriving from a self inactivating retroviral vector, resulting in deletion in both LTRs (in red). LTR, long 
terminal repeat; PBS, primer-binding site; PP, polypurine tract; tRNA, transfer RNA; ▲, deletion. Modified 
from Coffin et al, 1997. 
 
 
Viruses differ with respect to their tropism. Therefore, by replacing the 
env gene with that of another virus, the host range can be extended by a technique 
known as pseudotyping. Frequently the vesicular stomatitis virus G (VSVG) protein is 
used as the envelope, since it is relatively stable and its tropism is broad. Regarding the 
expression of the transgenes, it is unknown for both retro- and lentiviruses if it is 
necessary for the RNA to be either unspliced or partially spliced to be efficiently 
exported to the cytoplasm. As it is difficult to place splice sites in the virus vector 
backbone without affecting the efficacy of virus production, the Woodchuck hepatitis 
virus posttranscriptional element (WPRE) can be employed. WPRE stimulates nuclear 
exportation of intronless RNA, improving transgene expression from retro- or lentiviral 
vectors (Donello, Loeb et al. 1998; Zufferey, Dull et al. 1998). One requirement for 
retroviral integration is that the target cells is dividing. This restricts the use of this kind 
of vector to cells that are able to proliferate and excludes its use in non-dividing target 
cells such as hematopoietic stem cells and neurons. To overcome this limitation, 
lentiviral vectors can be used.  
 
 
 3.5.1.2.2 Lentivirus 
 
Lentiviruses are a subclass of retroviruses, which are able to infect both 
proliferating and non-proliferating cells. They can integrate into the genome of non-
proliferating cells due to two virion proteins: matrix and vpr. These proteins interact with 
the nuclear import machinery and mediate the active transport of the viral pre-
integration complex through the nucleopore (Bukrinsky, MI et al. 1993; Naldini, L et 
al.1996). Lentiviruses have a high complexity and additional genes including tat, rev, 
vpr, vpu, nef and vif. The production of lentiviruses differs from the production of 
retroviruses in regard to the packaging cell lines. In the packaging cell lines used for 
lentiviral production, viral genes are not kept permanently but are transiently induced via 
plasmids providing the pseudotyped env gene and the structural and regulatory genes 
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in trans. The transgene construct, however, is similar to that used to produce MoMLV 
based retrovirus vectors. Current lentiviral vectors are derived from the human 
immunodeficiency virus (HIV) and their safety profile seems to be approximately the 
same as for the retroviral vectors. 
 
 
3.5.2. Dendritic cells and immuno/gene therapy 
 
DCs play essential roles in both priming immune responses and in 
generation of central and peripheral tolerance. While DCs ability to initiate and stimulate 
effector cells have been extensively exploited in anti-tumor therapy, the regulatory 
functions of DCs in maintaining tolerance have generated considerable interest in 
harnessing them for Ag-specific immunotherapy of autoimmune diseases, allergic 
hyper-sensibility and transplantation. Indeed, several attempts using DCs for the 
treatment of cancer and autoimmune diseases have shown promising results. Among 
the different approaches, one of the most widely applied consists of loading DCs 
isolated from peripheral blood or differentiated from monocytes or bone marrow 
precursors, with a known Ag and then transferring them to the individual to be treated. 
Administration of genetically modified DCs with genes encoding immunoregulatory 
molecules or the Ag involved in the immune response is also an attractive strategy to 
circumvent undesired and/or exaggerated immunity. This approach has been used for 
example with: (I) DCs expressing Fas ligand, prolonging cardiac allograft survival in 
mice (Min, Gorczynski et al. 2000), (II) DCs expressing IL-4, resulting in suppression of 
murine arthritis (Kim, Kim et al. 2001), (III) and DCs expressing IL-12p40 or IL-10, 
suppressing collagen-induced arthritis (Nakajima 2006). Besides the difficulty of 
obtaining a sufficient amount of cells, a very negative aspect of these methodologies is 
the extensive manipulation and consequently undesired modification of the DCs. 
Moreover, considering that different subpopulations of DCs play specific functions in the 
immune system and that it is still not known how to differentiate or isolate all these 
different cells, the results obtained by such ex vivo manipulation are even more 
uncertain. Current possibilities to modify DCs in vivo without such a need for extensive 
handling are: (I) DCs targeted in vivo through antibodies against receptors expressed 
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mainly by DCs, as in the case of anti-DEC-205 antibodies conjugated to a protein to be 
processed and presented in context of the MHC (Bonifaz, 2002), (II) virus vaccination to 
transduce DCs in vivo (He, 2006), or (III) promoters that drive transgene expression 
specifically in certain DC populations, such as the fascin promoter that transcriptionally 
targets gene expression to cutaneous mature DCs (Ross, Sudowe et al. 2003). The 
disadvantages of these techniques are lack of long term transgene expression, 
unwanted immune responses against the virus used in the vaccination, and targeting of 
only some DC populations or states of maturation, which might result in restricted 
immune responses. Although all available techniques to modify DCs with clinical 
objectives present some faults, the positive results already achieved in the treatment of 
immune disorders have encouraged immunologists to continue investing this field, but 
have also reinforced the necessity of improvement of the current methodologies. 
 
 
3.6 Goals of the project 
 
The two basic objectives underlying this work were:  
(I) Transcriptionally target gene expression to DCs through the use of a viral 
vector suitable for gene therapy;  
(II) to test the use of the developed viral vector for induction of antigen-
specific tolerance in vivo.  
The project involved the following main steps:  
(I) Identification of a DC-specific promoter and its ability to drive transgene 
expression in different DC subpopulations in vivo; 
(II) Comparison of retrovirus and lentivirus as optimal vectors; 
(III) Test the efficiency of the system in inducing CD4 and CD8 T cell 
tolerance in vivo in different murine strains; 
(IV) Test the functionality of the system in human DCs in vitro. 
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4. Material and Methods 
 
Both material and methods are listed by alphabetical order. 
4.1 Material 
4.1.1 Antibodies 
Specificity 
(anti-mouse) 
Conju
gate 
Clone Source of supply 
B220 FITC RA3-6B2 BD Pharmingen (San Diego, CA, USA) 
CD3 PE 17A2 BD Pharmingen 
PE CD4 PerCP H129.9 BD Pharmingen  
CD8 PerCP 53-6.7 BD Pharmingen 
CD11b PE M1/70 BD Pharmingen 
CD11c APC HL3 BD Pharmingen 
PE CD19 APC 1D3 BD Pharmingen 
CD24 PE M1/69 BD Pharmingen 
CD25 PE PC61 BD Pharmingen 
PE IM7.8.1 Caltag CD44 APC IM7 BD Pharmingen 
CD45.1 FITC A20 BD Pharmingen 
FITC CD62L APC Mel14 BD Pharmingen 
CD69 PE H1.2F3 BD Pharmingen 
DX5 PE DX5 BD Pharmingen 
Foxp3 APC FJK-16s eBioscience (San Diego, CA, USA) 
Gr-1 PE RB6-8C5 BD Pharmingen 
FITC I-Ab PE AF6-1201 BD Pharmingen 
NK1.1 APC PK136 BD Pharmingen 
PDCA-1 PE JF05-1C2.4.1 Miltenyi Biotec 
FITC Vα2 TCR 
PE B20.1 BD Pharmingen 
FITC Vβ5.1/5.2 TCR 
PE MR9-4 BD Pharmingen 
Specificity 
(anti-human) 
Conju
gate 
Clone Source of supply 
CD1a APC HI149 BD Pharmingen 
CD14 PerCP M5E2 BD Pharmingen 
CD19 APC HIB19 BD Pharmingen 
 
Tabele 3: Antibodies used in flow citometry. All antibodies were titrated before use. 
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The MHC tetramers H-2kb/SIINFEKL (OVA257-264), H-2kb/SSIEFARL (HSVgB498-
505) and APC- conjugate were purchased from ProImmune (Oxford, UK). 
 
4.1.2 Chemicals 
All buffers and solutions were prepared using double distillated water. If not stated 
differently, all chemicals (maximal degree of purity) were purchased from Merck 
(Darmstadt), Roth (Karlsruhe) or Sigma (St. Louis, MO, USA). 
 
4.1.3 Consumable supplies 
Disposable syringe filter (0,2 + 0,45 µm; Nalgene Nunc Int., Rochester, NJ, USA), bottle 
filter (Nalgene Nunc Int. Rochester, NJ, USA), disposable injection needle 26 G x 1/2“ 
(Terumo Medical Corporation, Tokyo, Japan), disposable syringes (Braun, Melsungen, 
Germany), reactions container 0,2 ml (Nunc, Wiesbaden,Germany), reactions container 
1,5 ml und 2 ml (Eppendorf, Hamburg, Germany), reaction tubes 5 ml (Becton, 
Dickinson & Co., Franklin Lakes, NJ, USA), reaction tubes 15 ml und 50 ml (Greiner, 
Frickenhausen, Germany) 
 
Other materials and plastic wares were purchased from Falcon, Becton Dickinson 
(Franklin Labs. NJ, USA), Nunc (Wiesbaden, Germany) und Greiner (Frickenhausen, 
Germany). 
 
4.1.4 Devices 
Analytic scale (Adventurer, Ohaus Corp., Pine Brooks, NJ, USA), bench centrifuge 
(Centrifuge 5415 D, Eppendorf, Hamburg, Deutschland), “β-Counter“ (Wallac, Perkin 
Elmer, Turku, Finnland), centrifuge (Rotixa RP, Hettich, Tuttlingen, Deutschland), 
chemical scale (Kern, Albstadt), Flow cytometer (FACSCalibur von Becton Dickinson), 
incubator (Hera cell, von Heraeus Kendro Laboratory Products, Hanau, Deutschland), 
laminar airflow cabinet (Heraeus), magnetic stirrer (Ika Labortechnik, Staufen, 
Deutschland), PCR-machine (Biometra) pH-Meter (Inolab, Weilheim, Deutschland), 
pipettes (Gilson, Middleton, WI, USA), automatic pipettors (Integra Biosciences, Baar, 
Schweiz), power Supply (Amersham Pharmacia, Piscataway, NJ, USA), vacuumm 
pump (KNF Neuberger, Munzingen, Deutschland), vortex-Genie2 (Scientific Industries, 
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Bohemia, NY, USA), water bath (Grant Instruments Ltd., Barrington Cambridge, 
England). All other devices are mentioned in “methods” section. 
 
4.1.5 Medium and solutions 
ACK-Buffer      8,29 g NH4Cl  
       1 g KHCO3  
       37,2 mg Na2EDTA  
       H20 ad 1 l  
    pH 7,2-7,4 adjusted with1 N HCl and  
    sterilized by 0,2µm filtration 
 
PBS       150 mM NaCl  
       10 mM Na2HPO4  
       2 mM KH2PO4  
       pH 7,4 adjusted with 5 N NaOH  
 
PBS-FBS      Dulbecco’s PBS (Invitrogen, San Diego, 
       CA,USA) without Ca2+/Mg2+  
       2% FBS (v/v) (Invitrogen, San Diego, CA, 
       USA)  
  
FACS-buffer     PBS  
       2% FBS (v/v)  
       0,01% NaN3 (v/v)  
 
5-Fluoro-uracil (5-FU)         20 mg/ml in Dulbecco’s PBS (Gibco)  
           pH 10-11 adjusted with NaOH  
           vortexed until completely dissolved 
           pH 7,5 adjusted with HCl  
           Sterilized by 0,2µm filtration  
           Stored at –20°C  
 
MACS-buffer     Dulbecco’s PBS (Invitrogen, San Diego, CA, 
       USA) without Ca2+/Mg2+  
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       0,5 % BSA (m/v)  
       pH 7,4 adjusted with 5 N NaOH  
 
RFI          15% Glycerin (v/v) 
          100 mM KCl 
      50 mM MnCl2 
      30 mM C2H3KO2 
      10 mM CaCl2 
     pH 5,8 adjusted with 0,2 mM acetic acid 
           Sterilized by 0,2µm filtration  
           Stored at 4°C  
 
RFII         15% Glycerin 
         10 mM MOPS 
         10 mM KCl 
         75 mM CaCl2 
    pH 6,8 adjusted with 1 N NaOH  
          Sterilized by 0,2µm filtration  
           Stored at 4°C  
 
50x TAE-buffer     242g Tris 
       57,1 ml 100% (v/v) acetic acid  
    100 ml 0,5 M EDTA (pH 8,0) 
 
Solutions used for transfection 
2xHBS         50 mM HEPES 
          280 mM NaCl 
          1,5 mM Na2HPo4-Dihydrat 
          pH 7,05 adjusted with NaOH  
          Sterilized by 0,2µm Filtration  
          Stored at –20°C (≤ 6 months) 
 
CaCl2          2,5 M CaCl2 
           Sterilized by 0,2µm filtration  
           Stored at –20°C  
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Cell culture media 
All culture media and solutions were purchased from Gibco (ordered by Invitrogen, 
Carlsbad, CA, USA), unless otherwise stated. 
 
DC-Medium        Iscove’s Modified Dulbecco’s Medium 
    (IMDM) 
   5% FBS (inactivated, v/v) 
   500 mM β-Mercaptoethanol 
   100 U/ml Penicillin 
        100 µg/ml Streptomycin 
      25 ng/ml GM-CSF  
 
Freezing-Medium       90% FBS 
        10% DMSO 
 
HSC-Medium                  Stemline hematopoietic stem cell expansion 
medium 
        (Sigma-Aldrich, St. Louis, USA)  
        100 U/ml Penicillin 
        100 µg/ml Streptomycin 
        50 ng/ml hIL-6  
        10 ng/ml mIL-3 
        50 ng/ml mSCF 
 
Phoenix-Medium                              Dulbecco’s Modified Eagle Medium (DMEM) with 
                                                         Glutamax-I 
        10% FBS (inactivated, v/v) 
        100 U/ml Penicillin 
        100 µg/ml Streptomycin 
 
Phoenix-transfection medium       same as Phoenix-medium, plus 2.5mM  
        Chloroquine (Sigma) 
 
293T-Medium        DMEM Glutamax-I 
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       10% FBS (inactivated, v/v) 
       100 U/ml Penicillin 
       100 µg/ml Streptomycin 
       0.1 mM MEM non essencial  aminoacids 
       10 mM HEPES 
       500ug/ml Geneticin 
       2 mM L-glutamin 
 
293T-transfection medium      same as 293T medium, without geneticin 
 
4.1.6 Mouse strains 
All mice were maintained in the mouse facilities of the Institute of Immunology. LMU, 
Munich 
 
C57BL/6 and B6SJL 
The MHC-haplotype of this mouse strain is H-2b. Mice from the C57BL/6 strain express 
the allele Ly5.2 in all leukocytes. The congenic strain B6SJL is genetically identical to 
the C57BL/6 strain, except for expressing the allele Ly5.1 in all leukocytes. 
 
OT-I 
OT-I mice express a transgenic Va2/Vb5 TCR specific for the OVA257–264 peptide in the 
context of MHC-I H2-Kb (Hogquist, Jameson et al. 1994). These mice were bred onto 
the C57BL/6 and B6SJL background, i.e., the OT-I cells express the allele Ly5.2 and 
Ly5.1, respectively. 
 
OT-II  
OT-II mice have a transgenic Va2/Vb5 TCRs specific for the OVA323-339 peptide that can 
be recognized in the context of MHC-II I-Ab. (Robertson, Jensen et al. 2000). These 
mice were bred on the C57BL/6 background. 
 
RIP-OVAlo 
RIP-OVAlo mice express a membrane-bound form of OVA under control of the rat 
insulin promoter [RIP (Blanas and Heath 1999)]. In the pancreas and testis OVA is 
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expressed as a model auto-antigen. When RIP-OVAlo mice receive OT-I cells and are 
immunized, they develop diabetes. The progress of diabetes can be monitored by 
measuring the glucose concentration in the urine (Diabur 5000, Roche Diagnostic, 
Rotkreuz, Switzerland). 
 
4.1.7 Peptide, Protein and Oligonucleotides 
Chicken-ovalbumin (OVA albumin, chicken egg, Grade V) was purchased from Sigma 
(St. Louis, MO, USA). The peptides OVA257-264 and HSVgB 498-505 were purchased from 
Neosystems (Strassburg, France)  
 
The following nucleotides were purchased from MWG-Biotech AG (Ebersberg, 
Germany) 
 
Bdnf forw: 5'-ACGACATCACTGGCTGACAC-3' 
Bdnf rev: 5'-CATAGACATGTTTGCGGCATC-3' 
DC-STAMP forw: 5’-GCTGAGAGGCCTGAAAACAC-3’ 
DC-STAMP rev: 5’-CAGAGAGTACTTTTAAACCTGTCTTCT-3’ 
qPCR forw: 5'-TGAAAGCGAAAGGGAAACCA-3' 
qPCR rev: 5'-CCGTGCGCGCTTCAG-3' 
All sequencings were carried out by Sequiserve (Vaterstetten, Germany). 
 
4.1.8 Vectors 
4.1.8.1 Cloning vector  
For subcloning, the Plasmid pBluescript-II-KS+ (pBS; Stratagene, Amsterdam, 
Netherlands) was used. 
 
4.1.8.2 Herpes Simplex Vector 
The recombinant, replication deficient vector HSV-OVA was produced by P. Marconi 
(University of Ferrara, Italy).  
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4.1.8.3 Viral Vectors 
Retroviral vectors 
The retroviral vector used in this work was constructed based on SIN-SF (Kraunus, 
Schaumann et al. 2004). In this vector, the promoter/enhancer-containing region 
located in the 3’LTR was deleted. To generate DCSTAMP-eGFP-SIN-retrovirus, the 
DC-STAMP promoter was amplified by PCR from total genomic DNA of C57BL/6 mice 
using specific oligonucleotide primers (DC-STAMP forw and DC-STAMP rev) to amplify 
a 2552bp-fragment. The latter was digested with BbsI resulting in a product of 1704bp 
covering the region between -1565bp and +131, considering +1 as the first base pair of 
transcription initiation of DC-STAMP. This promoter containing region was cloned into 
SIN-CD19-TfrOVA-W (Werner-Klein, Dresch et al. 2007), previously digested with Not 
I/Klenow blunt ended/Nru I. 
 
Lentiviral vectors 
The lentiviral vectors used in this work are based on FUGW. In this vector, the 
promoter/enhancer-containing region located in the 3’LTR was deleted (Lois, Hong et 
al. 2002). To generate DCSTAMP-eGFP-SIN-lentivirus, the DC-STAMP promoter was 
isolated from DCSTAMP-eGFP-SIN-retrovirus through Pst I/Klenow blunt ended/Age I. 
This sequence was cloned into FUGW, that was digested with Pac I/Klenow blunt 
ended/Age I. DCSTAMP-mock-SIN-lentivirus was generated by digesting DCSTAMP-
eGFP-SIN-retrovirus with Xba I/Age I/ Klenow blunt ended and followed by religation. 
To generate DCSTAMP-trOVA-SIN-lentivirus, a plasmid containing the chimeric 
transferrinreceptor-OVA-cDNA (produced by Henning Lauterbach, subcloned into pBS 
and designated here trOVA-pBS), was digested with Sac II/Klenow blunt ended/Eco RI. 
This cDNA was then cloned into DCSTAMP-eGFP-SIN-lentivirus, which was digested 
with Age I/ Klenow blunt ended/ Eco RI. 
 
4.2 Methods 
 
4.2.1 Cellular and immunological methods 
4.2.1.1 Adoptive cell transfer 
This method allows tracing antigen specific T cells in vivo. The T cell population of 
interest is isolated from spleen and/or lymph nodes of a donor and transferred into the 
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recipient in sufficient amounts to be detected by flow cytometry. MACS (negative 
selection) was used for the isolation of the T cells to be transferred. The purity of T cells 
was determined, before transfer, by flow cytometry.  
 
4.2.1.2 Cell culture 
4.2.1.2.1 Culture and transduction of HSC 
Bone marrow cells of at least 6 weeks old C57BL/6, OT-I or OT-II mice were harvested 
4 days after intravenous (i.v.) injection of 5-FU (150 mg/kg body weight, Amersham 
Pharmacia, Uppsala, Sweden). The cells were cultured in 100 mm plates in a total 
amount of 10x106 cells/10 ml at 37°C and 5% CO2. Before tranduction, the cells were 
prestimulated for 2 days in serum-free Stemline Hematopoietic stem cell expansion 
medium (Sigma-Aldrich, St. Louis, USA), supplemented with penicillin-streptomycin 
(Gibco BRL, Invitrogen Corporation, Carlsbad, CA) and a growth factor cocktail 
containing human IL-6 (25 ng/ml), murine IL-3 (10 ng/ml) and murine SCF (50 ng/ml). 
Recombinant growth factors were purchased from Strathmann Biotech (Hannover, 
Germany). Cells were transduced by spin-infection (300xg, 2 hours, 32°C) with cell-free 
stocks of lentiviral vectors (MOI of 1) in the presence of protamine sulfate (4 µg/ml). If 
desired the transduction procedure was repeated 20-26 hours after the first round.  
 
4.2.1.2.2 Culture of dendritic cells 
For differentiation of DCs in vitro, 1x106/ml bone marrow cells were cultured in DC-
medium, in a total amount of 10 ml per 100 mm plate at 37°C and 5% CO2. Each 2-3 
days, fresh medium was added. DCs are viable under these conditions until day 9 of 
culture. When desired, transduction was performed at day 2 of culture with 1x106 
cells/ml, in a total of 2 ml per well in 6 well plates. The transduction protocol was the 
same for NIH3T3 cells. The human bone marrow cells (Cambrex, Walkersville, USA) 
were differentiated into DCs in vitro in RPMI medium supplemented with penicilin-
streptomicin, 10% foetal bovine serum and a cytokine cocktail containing human GM-
CSF (100ng/ml), IL-4 (20ng/ml) and TNF-α (20ng/ml), all purchased from Strathmann 
Biotech (Hannover, Germany). 
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4.2.1.2.3 Culture of 293T, Phoenix-eco and NIH3T3 cells 
Phoenix-eco and NIH3T3 cells were cultured in Phoenix-medium on 100 mm cell 
culture plates at 37°C and 5% CO2. 293T cells were cultured in 293T-medium on 100 
mm cell culture plates at 37°C and 10% CO2. All cells were split so that a confluence of 
less than 75% was mantained. Phoenix-eco cells stored at -180 °C longer than 6 
months, were selected during 2 weeks with 1 µg/ml Diphteria-Toxin (Calbiochem-
Novabiochem, San Diego, CA, USA) and 500 µg/ml Hygromycin B (CNbiosciences 
LTD., Beeston, UK). In the case of 293T, only cells with less than 30 passages were 
used. 
 
Management of NIH3T3 cells for virus titration 
NIH3T3 cells were plated at a concentration of 4x104 cells/well in 24-well cell culture 
plates 18-24 hours before transduction. A total of 9 wells per virus stock to be titrated 
were necessary to achive dilutions of 1/10, 1/50, 1/100 1/500, 1/1000, 1/5000, 1/10.000, 
1/25.000 and 1/50.000. An additional 3 wells were plated for counting the number of 
cells per well at the time of transduction. Each well was transduced with 500-1000ul of 
virus supernatant dilution in the presence of 8 ug/ul of polybrene (Hexadimethrine-
Bromid, Sigma, St. Louis, MI, USA). The plates were centrifuged at 300g, 32°C for 2 
hours and incubated at 32°C and 5% CO2 for a further 4 hours. The virus supernatant 
was then replaced with Phoenix-medium. After 24-48 hours, cells were harvested with 
Trypsin/EDTA and total genomic DNA was extracted for qPCR analysis.  
 
4.2.1.3 CFSE staining 
CFSE (carboxyfluorescein-diacetate-succinimidylester) staining is used with the aim of 
tracking cell division both in vitro and in vivo. CFSE binds to intra and extra cellular 
proteins and after each cell division, the dye is divided between the daughter cells and 
the intensity of the fluorescence (analyzed by flow cytometry) is reduced 50%. The 
number of cell divisions can be identified by the number of times that the stain was 
reduced by half. For the staining procedure, the single cell suspension to be labeled is 
depleted of erythrocytes (with ACK buffer), and washed two times with PBS. The cell 
pellet is resuspended in PBS (without FBS, since this inhibits the staining reaction) and 
5 uM CFSE is added per 1-50x106 cells. The cells are incubated for 10 minutes at 37°C 
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and protected from light. The reaction is stopped by addition of equal amount of FBS. 
The cells are washed 2 times with PBS and resuspended in the desired amount of PBS 
or culture medium. 
 
4.2.1.4 Extraction of blood and harvest of organs from mice  
a) Lymphocyte enrichment from peripheral blood  
Before blood extraction, the mice were kept under an infrared lamp to achive 
vasodilatation. A small cut was made in the tail so that 3-10 drops of blood could be 
extracted and mixed with 50 µl of Heparin-sodium (25000 I.E./5 ml, Ratiopharm, Ulm, 
Germany). Next, 2 ml of FACS buffer was added and mixed into each blood sample 
and, 1 ml of lymphocyte separation medium (PAA Laboratories, Linz, Austria) was 
added slowly to the bottom of the tube, so that the blood/buffer suspension was located 
on the upper part of the reaction tube. After centrifugation (30 minutes at 25°C and 
450g), the lymphocytes were harvested from the intermediate phase. The lymphocytes 
were then washed and resuspended in 50 µl of FACS buffer. 
 
b) Organs harvesting and preparation of single cell suspension  
Lymph nodes and spleen were harvested with fine tweezers and kept in FACS buffer on 
ice. For single cell preparation, organs were placed in a 100 µm cell strainer (BD 
Biosciences, Erembodegem, Belgium) and smashed through with a syringe plunger. 
The cells were resuspended in FACS buffer and centrifuged for 5 minutes at 4°C and 
300 g. The cells extracted from lymph nodes could be then resuspended in the desired 
amount of buffer or medium. Spleen cells were depleted of erythrocytes with ACK 
buffer.  
Bone marrow was extracted from femurs and tibias of mice. The extremities of the 
bones were cut off with scissors and the bone marrow was flushed out with medium 
using a needle and syringe. Cells were centrifuged for 5 minutes at 4°C and 300 g and 
resuspended in culture medium. 
 
c) Erythrocyte lysis 
After centrifugation, the single cell pellet was resuspended in 4 ml of ACK buffer and left 
for 4 minutes at RT. Afterwards, 10 ml of FACS buffer was added and the cell 
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suspension was centrifuged for 5 minutes at 4°C and 300 g and then resuspended in 
culture medium or FACS buffer. 
 
4.2.1.5 Flow cytometry - Fluorescence-Activated Cell Sorting (FACS) 
Flow cytometry permits simultaneous measurements of multiple parameters in single 
cells. Specific molecules or cluster of differentiation (CD) that are differentially 
expressed in certain leukocyte sub-populations, can be assessed by staining with 
fluorochrome-coupled monoclonal antibody specific for the surface molecules of 
interest.  
 
Staining procedure  
The identification of the cell populations and subpopulations using different antibodies 
were made according to a FACS marker profile for each cell type. Before staining, 50µl 
of a cell suspension was washed in 5 ml FACS-buffer at 300 g for 5 minutes. The 
supernatant was discarded and cells were resuspended in 100µl of antibody-containing 
buffer. The tubes were then incubated in the dark at 4°C for 20 minutes. The cells were 
washed 2 times to remove the excess of unbound antibodies and the supernatant 
discarded. Before acquisition, 200µl of PBS was added to the tubes. When intracellular 
staining was necessary, the intracellular Staining Set (eBioscience, San Diego, CA, 
USA) was used and staining was performed according to instructions of the 
manufacturer. The measurements were performed using a FACSCaliburTM-Flow 
Cytometer (Becton, Dickinson & Co., Franklin Lakes, NJ, USA) with two lasers. The 
data was acquired with CellQuest Software, Version 3.4 (Becton, Dickinson & Co., 
Franklin Lakes, NJ, USA) and analyzed with CellQuest- or FlowJo -Software (TreeStar, 
Ashland, OR, USA). 
 
4.2.1.6 Generation of bone marrow chimeras 
Bone marrow cells of at least 6 week old C57BL/6, OT-I or OT-II mice were harvested 4 
days after intravenous (i.v.) injection of 5-FU (150 mg/kg body weight, Amersham 
Pharmacia, Uppsala, Sweden). The cells were stimulated for 2 days in serum-free HSC 
medium. Cells were transduced and after the final transduction 1-3x106 cells/mouse 
were injected i.v. into lethally irradiated (550rad day -2 and day 0; Cesium-137, Model 
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G.C. 40; Type B (4); Atomic Energy of Canada Limited, Kanata ,Ontario, Kanada) 
C57BL/6 recipients. When stated, CD8+ cells were depleted by magnetic sorting before 
injection. Recipient mice received drinking-water containing neomycin (1,17g/l) for 3 
weeks after reconstitution. 
 
4.2.1.7 Immunization 
a) Immunization with antibody immuno-complexes 
Mice were immunized with rIgGαOVA-ovalbumin (or rIgG in the mock controls) 
immune-complexes and 20µg/mouse of CpG nucleotides (InvivoGen, USA). The 
complexes were formed with 25µg of rIgGαOVA (ICN Pharmaceuticals, USA) and 1µg 
of ovalbumin (Sigma, USA) for 30 minutes at 37°C. 
 
b) Immunization with recombinant Herpes Simplex Virus Type 1 (rHSV-1) 
The stock of virus was thawed on ice and resuspended with ultrasonic waves for 10 
seconds (Ultrason E, Greiner, Frickenhausen, Germany). The virus concentration was 
adjusted with PBS and 4x106 pfu of rHSV-1 expressing OVA was injected i.v. per 
mouse. 
 
4.2.1.8 in vivo killer assay 
This method permits the evaluation of the cytotoxic effector function of CD8+ T cells in 
vivo (Coles, Mueller et al. 2002). First, C57BL/6 erythrocyte-depleted splenocytes were 
incubated in the presence or absence of 10 µM of OVA257-264 peptide or HSVgB498-505 
peptide for 2 h at 37°C and 5% CO2. Peptide-loaded cells were labeled with a high (1.7 
µM) concentration of CFSE (Molecular Probes, USA), whereas unloaded cells, used as 
internal control, were labeled with a low concentration (0.2 µM) of CFSE. Equal 
numbers of CFSEhigh and CFSElow cells were mixed and analyzed by flow cytometry. 
2x107 total cells/mouse were administered i.v. 15-18 h later, mice were sacrificed and 
spleen cell suspensions were analyzed for the loss of peptide coated population by flow 
cytometry. The specific lysis is calculated as follows: 
 
Percentage of specific lysis (PSL)= 1- (r of unimmunized mouse/ r of immunized mouse) 
x 100. 
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r = (percentage CFSElow/ percentage CFSEhigh) 
 
4.2.1.9 Magnetic cell sorting (MACS)  
Magnetic cell sorting (MACS, Miltenyi Biotech, Bergisch-Gladbach, Germany) is a 
technique that allows isolation of different cell- subpopulations based on their 
expression of different antigens or CDs on the cell surface. For MACS separation, the 
mononuclear cells are incubated first with MACS colloidal super-paramagnetic 
MicroBeads conjugated to a specific monoclonal antibody with specificity towards the 
CD expressed by the cell-subpopulation to be isolated (positive selection) or to be 
eliminated (negative selection). The cells are applied to a column that is placed in a 
magnetic field of a MACS separator. There are different columns for different purposes 
and for different numbers of cells. The MS column is used for positive selection for up to 
107 cells. Labeled cells are retained by the magnetic field inside the column, while the 
unlabeled ones (negative fraction) are eluted. The column is washed three times with 
MACS buffer to remove the excess cells of the negative fraction. After removal of the 
column from the magnetic field, the cells retained in the column can be eluted and 
collected as the positive fraction. MACS separation was applied to purify DCs (CD11c 
Microbeads) and CD8+ T cells (CD8+ T cell Isolation Kit) from cells isolated from spleen, 
lymph nodes and thymus. All procedures were performed according to the instructions 
of the manufacturer. 
 
4.2.1.10 Production of supernatant containing viral vectors 
a) Lentivirus production 
293T cells were plated 14-18 hours before transfection (6x106 cell per 100 mm cell 
culture plate) and kept at 37°C in a 10% CO2 incubator. Before transfection, 10 ml of 
pre-warmed 293T-transfection medium replaced the normal cell culture medium in each 
plate. For the transfection solution, 20 µg of vector plasmid, 15 µg of pCMVdR8.2 and 
10 µg of VSV-G were mixed with 100 µl of CaCl2 and water sufficient for 1 ml of total 
volume. 1 ml of HBS 2X was added while vortexing. This solution was carefully added 
in the plates containing the Phoenix cells and incubated for 3-5 hours. Afterwards, cells 
were washed with pre-warmed PBS and cultured in 10 ml of 293T-medium. Cells were 
kept at 37°C in a 10% CO2 incubator and after 24, 36 and 48 hours post-transfection, 
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medium was harvested and filtered (0.45 µm filter, Nalgene, Rochester NY). Virus was 
concentrated by filtration (Centricon Plus-70, Millipore, Bredfoard, MA, USA). Until use, 
the virus containing supernatant was stored at –80°C. 
 
b) Retrovirus production 
Phoenix-eco cells were plated 18 hours before transfection (7,5x106 cell per 100 mm 
cell culture plate) and kept at 37°C in a 5% CO2 incubator. Before transfection, 8 ml of 
pre-warmed Phoenix-transfection medium replaced the medium of each plate. For the 
transfection solution, 60 µg of vector plasmid was mixed with 75 µl of CaCl2 and water 
sufficient for 750 µl. While vortexing, 750 µl of HBS 2X was added. This solution was 
carefully added to the plates containing the Phoenix cells and incubated for 4-6 hours. 
Afterwards, cells were washed with pre-warmed PBS and 10 ml of Phoenix-medium 
was added. Cells were kept in a 32°C, 5% CO2 incubator and after 24, 36 and 48 hours 
post-transfection, medium was harvested and filtered (0.45 µm filter, Nalgene, 
Rochester NY, USA). Until use, the virus containing supernatant was stored at –80°C. 
 
4.2.1.11 T cell proliferation in vitro 
Splenocytes from OT-1 mice were prepared as a single cell suspension and T cells 
were isolated by MACS with CD8 microbeads. Afterwards, T cells were stained with 
CSFE and resuspended in culture medium. DCs were differentiated in vitro from BM 
isolated from chimeric mice. DCs that have been in culture for 6-8 days were used for 
the assay. As a positive control, DCs were loaded with 1 µg/ml of SIINFEKL peptide 
during 2 hours at 37°C and 5% CO2. Subsequently, 0.5 x 106 DCs were culture together 
with 0.5 x 106 T cells. After 72 hours the cells were harvested, stained and analyzed by 
flow cytometry. 
 
4.2.2. Molecular biology methods  
 
4.2.2.1 Agarose gel electrophoresis 
This technique was used to identify and isolate DNA fragments. The amount of agarose 
used depended on the size of the DNA fragment to be identified or isolated (0.8-2% 
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w/v). The samples were compared to a 100bp or 1kb ladder (Invitrogen, Carslbad, CA, 
USA). The separation of the DNA fragments was obtained under a constant voltage of 
80 in an electrophoresis chamber. (Repair workshop, Institute of Immunology, Munich, 
Germany). The visualization of the DNA was achived using ethidium bromide (0.005% 
added in the gel) under UV light (312 nm, Intas, Göttingen, Germany).  
 
4.2.2.2 Cleavage of DNA with restriction enzymes 
Restrictions enzymes were used to characterize and identify DNA fragments, as well as 
to prepare DNA sequences for cloning. All restrictions enzymes were purchased from 
New England Biolabs (Beverly, MA, USA) and were used according to instructions of 
the manufacturer. 
 
 4.2.2.3 Culture of bacteria 
Transformed bacteria were cultured in LB-medium (ICN Biomedicals, Aurora, Ohio, 
USA) at 37°C O/N. Since all plasmids and vectors contained an ampicilin resistance 
gene, 100µg/ml of ampicilin was added in the LB medium. For culture in solid medium, 
plates containing LB-agar were used (7.5g Agar/500 ml LB-Medium, containing 
100µg/ml of ampicilin). 
 
4.2.2.4 DNA and RNA isolation and purification 
The following kits were used for the respective objectives according to instructions of 
the manufacturer. All kits were purchased from Qiagen (Qiagen GmbH, Hilden, 
Germany), unless stated otherwise: 
Purification of DNA fragments from agarose gel  QIAquick® Gel Extraction Kit 
 
Isolation of small amounts (up to 20µg) of  QIAprep Spin Miniprep Kit 
plasmidial DNA     
   
Isolation of large amounts of plasmidial DNA  QIAfilter Plasmid Maxi Kit 
 
Isolation of genomic DNA   DNeasy Tissue Kit 
 
Isolation of total RNA   PureLink Micro-to-Midi (Invitrogen,  
   Carlsbad, CA, USA) 
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4.2.2.5 Ligation of DNA fragments 
The ligation reaction was carried out using 100 ηg of vector DNA and 300-400ηg of 
insert DNA in ligase buffer with 400U T4-Ligase (New England Biolabs, Beverly, MA, 
USA). The reaction was performed at RT for 30 minutes or at 4°C O/N. 
 
 4.2.2.6 Polymerase chain reaction (PCR) 
a) PCR for cloning 
When a DNA sequence was amplified for cloning, Pfu DNA-Polymerase was used 
(Stratagene, La Jolla, CA, USA). Compared to the other thermostable polymersases 
normaly used, Pfu amplifies DNA with a higher fidelity. The error rate is six-fold lower 
than when, for example, Taq polymerase is used. The PCR product was purified and 
sequenced. 
 
PCR reaction conditions 
5-50 ηg DNA 
0,5 µM primer forw  
0,5 µM primer rev 
1 x Pfu buffer 
200 µM dNTP mix (10 mM each) 
2,5 U Pfu DNA polymerase  
H2O sufficient for 50 µl  
The approximated melting temperature (TM) and the annealing temperature (TA) used 
initially, and adjusted if necessary, were calculated accordingly with the following 
formulas: 
TM = [(G+C) x 4°C] + [(A+T) x 2°C] 
TA = TM-5°C 
 
The amplification conditions were as follows 
5 min 95ºC 
       30 sec 95ºC 
30 sec TA (varied according to the primers used)  
1-4 min 72ºC (2 min/kb) 
       10 min 72ºC 
 
30 cycles  
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b) Quantitative PCR (qPCR) for virus titer determination 
NIH genomic DNA was purified and resuspended in 100µl of water. Real-time qPCR 
was performed with the LightCycler System (Roche Diagnostics, Penzberg, Germany). 
The virus backbone and the single-copy housekeeping gene Bdnf (used as internal 
standard control) were amplified using specific primers. Each sample was measured in 
duplicates using SYBR green I (Roche, Indianapolis, USA). Standard curves were 
generated using serial dilutions of DNA from a plasmid containing the region amplified 
with the respective primers.  
 
qPCR Reaction conditions 
200 ηg DNA 
750 ηM primer forw (1000 ηM for Bdnf) 
200 ηM primer rev (1000 ηM for Bdnf) 
1x Master SYBR Green I mix 
3 mM MgCl2 
H2O sufficient for 20 µl  
 
The amplification conditions were as follows: 
 
 2 min 50ºC 
 10 min 95°C 
        10 sec 95ºC 
 5 sec 58°C  
        10 sec 72ºC  
 1 min 65ºC 
 30 sec 40°C 
 
The final calculation of the virus titer was done using the following formulas: 
Virus titer (TU/ml)= No. of NIH cells transduced x No. virus copy per genome 
  volume of virus supernatant (ml) 
 
MOI= volume of virus supernatant (ml) x virus titer (TU/ml) 
            No. of cells 
 
 
40 cycles  
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4.2.2.7 Production of chemo competent bacteria  
One single colony from a culture of E. coli DH5α or Stbl3™ (Invitrogen, Carlsbad, CA, 
USA) was incubated O/N in LB medium without ampicilin. The following day, 1ml of this 
culture was diluted in 99ml of LB medium containing 10mM of MgCl2 and incubated at 
37°C in a shaker, until an OD600 of 0,4-0,6 was reached. The bacteria-containing 
medium was then left on ice for 10 minutes, followed by centrifugation at 3000g, 4ºC for 
25 minutes. The pellet was resuspended in 40ml of RFI medium and left on ice for 15 
minutes. After centrifugation, the pellet was resuspended in 4ml of RFII medium and 
incubated on ice for another 15 minutes. Aliquots of 100µl were stored at – 80°C. 
 
The Escherichia coli (E. coli) DH5α strain was used for transformation of SIN-retrovirus 
and pBS. The Stbl3™ E. coli strain is designed for cloning direct repeats found in 
lentiviral expression vectors. These cells reduce the frequency of unwanted 
homologous recombination of LTRs found in lentiviral vectors.  
 
4.2.2.8 Transformation of CaCl2-competent bacteria: 
For each transformation, 100 µl of frozen cells was thermed on ice for 10 minutes. 
Afterwards, the plasmid DNA was added to the bacteria and the whole mix was chilled 
on ice for 30 minutes. The cells were then heat shocked at 42 ºC for 30 - 45 seconds 
and the vial placed directly back on ice before being transferred into 0.9 ml of LB agar 
and grown for 1 hour at 37 ºC with shaking. The cells were then plated on 
agar/ampicillin plates and incubated O/N at 37 ºC. 
 
4.2.3 Sequence analysis 
Database searches for homologous genes and proteins were performed using the 
BLASTp and BLASTn algorithms (Altschul, Madden et al. 1997) at the server of the 
NCBI (http:www.ncbi.nlm.nih.gov/Blast). Promoter analysis was performed using the 
Genomatix software (www.genomatix.de). Primers were designed with the assistance of 
Primer3 software (http:www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). For 
general manipulation of the sequences, the tools of the BMC Search Launcher 
(http:searchlauncher.bcm.tmc.edu/seq-util/seq-util.html) were used. 
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4.2.4 Statistical Analysis: 
Data were analyzed using the Student’s t test (GraphPad Prism 4.03; GraphPad 
Software). A value of p<0.05 was considered significant. All experiments consisted of at 
least 3 mice per group, unless otherwise stated. 
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5. Results 
 
5.1 The murine DC-STAMP promoter presents all basic properties 
required to drive transgene expression from a viral vector. 
 
The first step to achieve lentivirus-mediated transgene expression 
specifically in DCs, was to identify a protein which is synthesized specifically in these 
cells. The DC-specific transmembrane protein (DC-STAMP) was first identified in 
monocyte-derived human DCs (Hartgers, Vissers et al. 2000), and later in murine DCs 
(Eleveld-Trancikova, Triantis et al. 2005). Although preferentially expressed in DCs, the 
role of this molecule has so far only been described as being involved in 
osteoclastogenesis (Kukita, Wada et al. 2004; Yagi, Miyamoto et al. 2005). DC-STAMP 
was chosen because as opposed to other molecules expressed on DCs, DC-STAMP 
was described not simply as being expressed preferentially by these cells but also as 
being expressed in both immature and mature DCs. In addition, it is highly conserved 
between human and mice (Hartgers, Vissers et al. 2000; Eleveld-Trancikova, Triantis et 
al. 2005), suggesting that its promoter could also be used to target human DCs. 
Moreover, when mRNA expression of DC-STAMP was compared with CD11c (a beta 2 
integrin expressed mainly in DCs), DC-STAMP showed a higher expression level 
(Hartgers, Vissers et al. 2000), suggesting that this promoter may be strong.  
Because DC-STAMP was previously described only in human cells, a 
computational analysis was performed to find its murine homologue. The full-length 
human DC-STAMP transcript of 1954 bp and its corresponding open reading frame 
(ORF) of 1410 nucleotides were previously described (Hartgers, Vissers et al. 2000). 
The encoded amino acid sequence (GenBank access no. AF305068) was used to 
perform a protein-protein blast (blastp) search (Altschul et al., 1997) against the nr (non-
redundant) database of the GenBank to detect the murine ortholog. A unique protein 
(GenBank access no. NM_029422) showing a high level of homology (74% of identity 
and 86% of similarity) with human DC-STAMP was identified. (Fig. 3). 
(http://www.ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid=10090).  
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transmembrane 7 superfamily member 4 [Mus musculus] Length=470 aa 
  
Identities = 349/468 (74%), Positives = 403/468 (86%),  
  
Human  1    MGIWTSGTDIFLSLWEIYVSPRSPGWMDFIQHLGVCCLVALISVGLLSVAACWFLPsiia  60  
            M +WT GT IFL LW  YV PRSP W+DFIQHLGVCC VA +SV L S A  W LP +    
Mouse  1    MRLWTLGTSIFLRLWGTYVFPRSPSWLDFIQHLGVCCFVAFLSVSLFSAAFYWILPPVAL  60  
  
Human  61   aaaswiiTCVLLCCSKHARCFILLVFLSCGLREGRNALIAAGTGIVILGHVENIFHNFKG 120  
             ++ W+ITCV LCCSK ARCFILL  LSCGLREGRNALIAAGTG+VI GHVENIF+NF+G  
Mouse  61   LSSVWMITCVFLCCSKRARCFILLAVLSCGLREGRNALIAAGTGVVIFGHVENIFYNFRG 120  
  
Human  121  LLDGMTCNLRAKSFSIHFPLLKKYIEAIQWIYGLATPLSVFDDLVSWNQTLAVSLFSPSH 180  
            LLD MTCNLRAKSFS+HFPLLK+Y EAIQWIYGLATPL++FDDLVSWNQTL VSLFSPSH  
Mouse  121  LLDSMTCNLRAKSFSVHFPLLKRYTEAIQWIYGLATPLNLFDDLVSWNQTLVVSLFSPSH 180  
  
Human  181  VLEAQLNDSKGEVLSVLYQMATTTEVLSSLGQKllafaglslvllgTGLFMKRFLGPCGW 240  
             LEA +ND++GEVL VL+ M  TTE+L+S+GQKLLA AGL L+L+ TGLF+KRFLGPCGW  
Mouse  181  ALEAHMNDTRGEVLGVLHHMVVTTELLTSVGQKLLALAGLLLILVSTGLFLKRFLGPCGW 240  
  
Human  241  KYENIYITRQFVQFDERERHQQRPCVLPLNKEERRKYVIIPTFWPTPKERKNLGLFFLPI 300  
            KYEN+YIT+QFV+FDE+ERHQQRPCVLPLNK+ER+KYVI+P+   TPKE+K LGLFFLP+  
Mouse  241  KYENVYITKQFVRFDEKERHQQRPCVLPLNKKERKKYVIVPSLQLTPKEKKTLGLFFLPV 300  
  
Human  301  LIHLCIWVLFAAVDYLLYRLIFSVSKQFQSLPGFEVHLKLHGEKQGTQDIIHDSSFNISV 360  
            L +L +WVLFAAVDYLLYRLI S++KQFQSLPG EVHLKL GEKQGTQ ++HDS+FNIS+  
Mouse  301  LTYLYMWVLFAAVDYLLYRLISSMNKQFQSLPGLEVHLKLRGEKQGTQGVVHDSAFNISM 360  
  
Human  361  FEPNCIPKPKFLLSETWVPlsvillilvmlgllssilmQLKILVSASFYPSVERKRIQYL 420  
            FEP+CIPKP+  +SETWVPLS+ILL L++LGLLSS+LMQLKILVS SFYP VER+RI+YL  
Mouse  361  FEPSCIPKPRLSVSETWVPLSIILLTLIILGLLSSMLMQLKILVSVSFYPKVERERIEYL 420  
  
Human  421  HAKLLKKRSKQPLGEVKRRLSLYLTKIHFWLPVLKMIRKKQMDMASAD  468  
            HAKLL+KRSKQPL E   + SLY  KIHFW PVLKMIRKKQ   A+ D  
Mouse  421  HAKLLEKRSKQPLREADGKPSLYFKKIHFWFPVLKMIRKKQTIPANED  468  
 
Figure 3: Results of a blastp alignment of the human DC-STAMP protein and the Mus musculus 
homologue (transmembrane 7 superfamily member 4). Identical amino acid positions between the 
two sequences (74%) are labeled in bold. Conserved amino acids (86%) between the two DC-STAMP 
proteins are assigned as (+). aa, amino acid.  
 
 
The location of the nucleotide sequence encoding the murine DC-STAMP 
protein and its mRNA were identified in the genome (Fig. 4). This allowed us to design 
primers to amplify the 5’ untranslated region (UTR) where the promoter regulatory 
sequences were expected. A sequence of 1704bp covering the region between -
1565bp and +131 (considering +1 the transcriptional start site) was chosen and 
subcloned into the SIN-retrovirus and the SIN-lentivirus vectors. 
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Figure 4: Mouse database browser display of the nucleotide sequence of the mus musculus 
chromosome containing the DC-STAMP gene. DC-STAMP is annotated in the database as Tm7sf4. 
The mRNA is indicated by a blue arrow over the sequence (mRNA-transmembrane). The region 
upstream of the mRNA (and the initial 131 nucleotides) contains the promoter region used in our studies. 
Numbers refer to the nucleotide positions in chromosome 15. Mouse sequences are available at  
(http://www.ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid=10090). 
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5.2 The murine DC-STAMP promoter confers DC specific transgene 
expression in vivo when delivered by a lentiviral vector, but not by a 
standard retroviral vector.  
 
The great advantage of using retroviral vectors for gene transfer is that the 
transgene sequences are integrated into the genome of the infected cell, thereby 
conferring stable transgene expression. Stability is particularly important when the cells 
to be transduced are HSC with the aim of targeting transgene expression to 
differentiated HSC-progeny. In order to develop a retrovirus allowing transgene 
expression mainly in DCs, we replaced the human CD19 promoter from a retroviral 
vector intended to target expression in B cells (Werner, Kraunus et al. 2004) with the 
DC-STAMP promoter to generate DCSTAMP-eGFP-SIN-retrovirus (Fig. 5a).  
One of the most important limitations of the SIN retrovirus is the relatively 
low virus titer obtained. This titer is inversely proportional to the size of the transgene 
inserted into the backbone. Low titers from SIN retroviral vectors have been associated 
with inefficient polyadenylation of the viral RNA due to extensive deletions made to the 
U3 region of the 3’ LTR. Such deletions included the TATA box affecting the nearby R 
region, which is implicated in polyadenylation (Yee JK, 1987; zufferey R, 1998). As in 
HIV the main cis-acting element governing polyadenylation is located in a region distal 
to the TATA box (DeZazzo JD, 1991; Valsamakis A, 1991; Valsamakis A, 1992). HIV–
derived vectors tolerate large U3 deletions without altering viral titers (Zufferey R, 
1998). Since we were not able to reach good viral titers with the SIN-retrovirus vector, 
we decided to try a parallel approach using a SIN-lentivirus vector. To this end, we 
replaced the human ubiquitin promoter from a SIN-lentiviral vector (Lois, Hong et al. 
2002) with the DC-STAMP promoter to construct the DCSTAMP-eGFP-SIN-lentivirus 
(Fig. 5b). As expected, by transducing mouse bone marrow derived DC cultures with 
identical volumes of DCSTAMP-eGFP-SIN-lentivirus or DCSTAMP-eGFP-SIN-
retrovirus, we were able to show that the titers of the SIN-lentivirus vector stocks were 
much higher than those of the SIN-retrovirus (Fig. 5).  
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Figure 5: DCSTAMP-eGFP self-inactivating retroviral and lentiviral vectors confer transgene 
expression in DCs in vitro. Schematic representation of (a) retroviral and (b) lentiviral-based SIN-
vector, with the murine DC-STAMP promoter to control expression of eGFP-cDNA. Bone marrow cells 
from C57BL/6 mice were cultured in presence of GM-CSF and 2 days later, transduced with DCSTAMP-
eGFP or DCSTAMP-mock (encoding no cDNA) retroviral or lentiviral vectors. Cells were analyzed for 
eGFP-expression by flow cytometry at day 7 of culture. Numbers in quadrants represent percentages of 
cells. CMV, cytomegalovirus; SIN, self-inactivating; LTR, long terminal repeat; WPRE, woodchuck 
hepatitis virus post-transcriptional regulatory element; △U3, deletion in the U3 region.  
 
 
In order to evaluate the specificity and potency of the DC-STAMP promoter 
in vivo, we generated mouse BM chimeras by reconstituting lethally irradiated mice with 
hematopoietic stem cells transduced two times with DCSTAMP-eGFP-SIN-retrovirus or 
a 
b 
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DCSTAMP-eGFP-SIN-lentivirus. 8 weeks after transplantation, we analyzed eGFP 
expression in the main populations of splenocytes (Fig. 6). While in the chimeras 
generated with DCSTAMP-eGFP-SIN-retrovirus only unspecific background of 
fluorescence in all cells was detected (Fig. 6, bottom), in the chimeras produced with 
DCSTAMP-eGFP-SIN-lentivirus eGFP expression was mainly restricted to DCs, with 
significant expression also in monocytes. However, no significant levels of eGFP 
expression could be observed in T cells, B cells or NK cells (Fig. 6, top).  
 
 
 
 
Figure 6: Murine DC-STAMP promoter targets transgene expression to dendritic cells in vivo 
when delivered by a lentiviral, but not a retroviral vector. Bone marrow HSCs from 5-FU treated 
C57BL/6 donor mice was transduced twice with DCSTAMP-retroviral or DCSTAMP-lentiviral vectors 
encoding eGFP (DCSTAMP-eGFP-SIN, red) or no cDNA (mock, blue) and 1-3 x 106 cells were injected 
into lethally irradiated recipient mice. At 8 weeks post-transplantation, chimeras were sacrificed, and cells 
were analyzed for eGFP expression by flow cytometry. The histograms represent FACS analyses of the 
indicated leukocyte populations from spleen, gated for the corresponding markers. CD11b was gated in 
the CD11c- population. NK cells were identified as DX5+NK1.1+. At least 3 mice per group were used. 
 
 
Since only DCSTAMP-eGFP-SIN-lentivirus but not -retrovirus gave 
promising results, we performed further detailed analysis only in chimeras generated 
with DCSTAMP-eGFP-SIN-lentivirus. The high eGFP MFI (mean of fluorescence 
intensity) indicates that besides being specific, DC-STAMP is also a strong promoter in 
the context of SIN-lentivirus (Fig. 7a, bottom). After two rounds of transduction of HSCs 
with virus concentrations ranging between MOI 0.2 and 1.5, the high DC-selectivity of 
transgene-expression was maintained. This specific expression could be observed in 
spleen, lymph nodes and thymus (Fig. 7 and data not shown). In addition, with 
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increasing viral titers, the expression levels of eGFP were amplified correspondingly 
(Fig. 7). Interestingly, despite an apparent tendency for the DC-STAMP promoter to 
drive transgene expression in myeloid cells, “lymphoid” CD8+ DCs also expressed high 
levels of eGFP (Fig. 7a). Taken together, these data suggest that the DC-STAMP 
promoter region used in the SIN-lentivirus is suitable to target transgene expression to 
different DC subpopulations in vivo. 
 
 
 
Figure 7. DC-selectivity of transgene expression is maintained in vivo after transduction with 
different MOIs. Bone marrow HSCs from 5-FU treated C57BL/6 donor mice were transduced twice with 
DCSTAMP-eGFP lentivirus vector, and 1-3 x 106 cells were injected into lethally irradiated recipient mice. 
At 8 weeks post-transplantation, chimeras were sacrificed, and cells were analyzed by flow cytometry. (a) 
Percentage (upper panel) and mean fluorescence intensity (MFI, lower panel) of eGFP positive cells 
within the indicated cell populations from chimeras generated with HSCs transduced twice with the 
indicated MOI. The leukocyte populations were gated accordingly with the indicated marker or as follow: 
DCs are correspondent to CD11c+ cells; pDCs were identified as CD11c+B220+ cells; monocytes are 
correspondent to the CD11b+CD11c- population; B cells were identified as CD19+ B220+ cells; NK cells 
were identified as DX5+NK1.1+. (b) Percentage of eGFP+CD11c+ cells in thymus and lymph nodes from 
the same chimeras as in (a). 
a 
   b 
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5.3 Transgene expression controlled by the DC-STAMP promoter 
leads to deletion of autoreactive antigen-specific CD4+ T cells in vivo. 
 
As shown in previous studies, DCs are able to delete autoreactive CD4+ T 
cells in the thymus (Brocker, Riedinger et al. 1997; Gallegos and Bevan 2004). In order 
to evaluate the functionality of our system, we wanted to test if mice reconstituted with 
bone marrow transduced with our lentiviral vector encoding ovalbumin (OVA) would 
develop OVA-specific tolerance. To this end we chose the TCR transgenic OT-II mouse 
strain in which CD4+ T cells recognize OVA peptide in the MHC-II context (Barnden, 
Allison et al. 1998). We generated a lentiviral vector expressing cDNA encoding for a 
chimeric non-secreted membrane-bound form of OVA [trOVA; (Diebold, Cotten et al. 
2001)] from the DC-STAMP promoter, giving rise to the DCSTAMP-trOVA lentivirus 
vector (Fig. 8).  
 
 
 
 
Figure 8: DCSTAMP-trOVA self-inactivating lentiviral vector. Schematic representation of lentiviral-
based SIN-vector, with the murine DC-STAMP promoter controlling expression of trOVA-cDNA. CMV, 
cytomegalovirus; SIN, self-inactivating; LTR, long terminal repeat; WPRE, woodchuck hepatitis virus 
post-transcriptional regulatory element; △U3, deletion in the U3 region.  
 
 
Next, we generated bone marrow chimeras from Ly5.2+ OT-II donors 
transduced with DCSTAMP-trOVA or DCSTAMP-mock lentivirus and transferred these 
cells into lethally irradiated congenic Ly5.1+ B6 recipients. In these chimeras, 
developing thymocytes and mature T cells would recognize their cognate antigen only 
on DCs, enabling us to monitor DC-functions and influence on CD4+ T cells. We 
observed significant reduction in the frequency of CD8-CD4+ T cells specific for OVA 
peptide in the thymus of DCSTAMP-trOVA chimeras, when compared with DCSTAMP-
mock transduced recipients (p<0.0001, Students’s t test, Fig. 9). Furthermore, the 
frequencies of total CD8-CD4+ thymocytes were significantly decreased in DCSTAMP-
trOVA chimeras, in contrast with DCSTAMP-mock chimeras (p=0.0003, Student’s t test, 
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Fig. 9 left). This decrease in the OT-II compartment was not due to reduced chimerism, 
since at least 96% of thymocytes were from donor phenotype (Fig. 9, right).  
 
 
 
 
Figure 9: DC-STAMP promoter-regulated expression of OVA in dendritic cells leads to Ag-specific 
central tolerance induction in TCR-transgenic CD4+ T cells. Bone marrow HSCs from OT-II mice 
were transduced with DCSTAMP-trOVA or DCSTAMP-mock lentivirus vector, and bone marrow chimeras 
were generated. At least 5 weeks after transplantation, chimeras were sacrificed, and cells were analyzed 
by flow cytometry. Thymocytes were gated on single positive CD4 cells, and OT-II cells were identified 
according to their expression of TCRVα2 and TCRVβ5.1/5.2; total numbers of thymocytes and total 
numbers of OT-II cells in both types of chimeras were compared (**, p= 0.004; ***, p=0.0003, Student’s t 
test). At least 3 mice per group were analyzed. 
 
 
Next, we analyzed spleens of these chimeras for presence of OT-II 
cells. The frequencies in OT-II cells were nearly 20-fold reduced in spleens from 
DCSTAMP-trOVA chimeras, resulting in an approximately 50-fold reduction in total 
numbers of OT-II cells, as compared to DCSTAMP-mock chimeras (Fig. 10a, right). The 
few remaining OT-II cells showed expression of specific surface activation markers, 
such as CD44, CD69 and CD25 and down-regulated CD62L (Fig. 10b), probably 
reflecting the constant interaction between OT-II and OVA-expressing DCs. The same 
reduction in the percentage of OT-II cells was still observed 30 weeks post-
transplantation, indicating that the expression of the transgene is long lasting. 
Moreover, when the bone marrow from these 30 weeks post-transplantation chimeras 
were differentiated in DCs in vitro, and these cells were co-cultured with CD8+ T cells 
expressing a transgenic TCR specific for OVA peptide in the context of MHC-I [OT-I 
cells; (Hogquist, Jameson et al. 1994)], only the T cells cultured with DCSTAMP-trOVA 
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derived DCs expanded (Fig. 10c). T cell proliferation was accompanied by IL-2 receptor 
(CD25) up-regulation, indicating T cell activation. The observed proliferation was nearly 
as strong as cell-division induced by mock-transduced DC loaded with the OVA-MHC 
class I peptide SIINFEKL (Fig. 10c). This data indicates that lentivirus vector mediated 
transgene expression was not silenced in DCs, as described previously in ubiquitous 
retroviral systems (Lindemann c, 2002).  
 
 
Figure 10: DC-STAMP promoter-regulated expression of OVA in dendritic cells leads to Ag-
specific peripheral tolerance induction in TCR-transgenic CD4+ T cells. Bone marrow HSCs from 
OT-II mice were transduced with DCSTAMP-trOVA or DCSTAMP-mock lentivirus vector, and bone 
marrow chimeras were generated. After at least 5 weeks following transplantation, chimeras were 
sacrificed and cells were analyzed by flow cytometry. (a) Expression of Vα2 and Vβ5.1/5.2 on CD4+ OT-II 
cells from spleen; total numbers of splenocytes and total numbers of OT-II cells in both types of chimeras 
were compared (*p=0.0195; *p=0.0169, respectively, Student’s t test). (b) OT-II cells from spleens were 
identified as described in (b) and expression of the indicated surface molecules was analyzed in 
a 
b 
c 
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DCSTAMP-trOVA- (open histogram) and mock- (grey histogram) chimeras. (c) Bone marrow cells from 
DCSTAMP-trOVA, mock or normal B6 mice were differentiated into DCs in vitro with GM-CSF. At day 7 
of culture, DCs were harvested and cultured (DCSTAMP-trOVA and mock), or loaded with 1 ug/ml of 
SIINFEKL peptide (SIINFEKL) and cultured with CSFE-labeled OT-I cells. As a control, OT-I cells were 
cultured alone (negative). At day 3 of culture, OT-I cells were analyzed by gating on CD8+ T cells. At least 
3 mice per group were analyzed. 
 
 
Some studies indicate that DCs can promote the differentiation of Tregs 
(Watanabe, Wang et al. 2005). Because CD25 was up-regulated in the remaining OT-II 
cells in the peripheral lymphoid organs of DCSTAMP-trOVA chimeras (Fig.10b), we 
analyzed these cells for the presence of the transcriptional factor forkhead box P3 
(foxp3) in CD4+TCRVa2+ T cells. Foxp3 is specifically expressed in CD4+ Tregs (Hori, 
Shohei et al. 2003), and in normal mice approximately 10% of all peripheral CD4+ T 
cells are CD25+Foxp3+. We observed significant increase in the frequency of 
Foxp3+CD4+TCRVa2+ T cells in the splenocytes isolated from DCSTAMP-trOVA 
chimeras when compared with DCSTAMP-mock transduced recipients (p=0.0024, 
Student’s t test, Fig. 11). However, no significant difference in total numbers of 
Foxp3+CD4+TCRVa2+ T cells was observed (Fig.11). Although further studies are 
necessary to address in more detail the generation of Tregs by lentiviral vector-
mediated antigen expression by DCs, these findings suggest that it does not lead to the 
differentiation of Tregs under steady state conditions. Nevertheless, efficient and long-
lasting Ag-specific CD4+ T cell deletion was induced. 
 
 
Figure 11: DC-STAMP promoter-regulated expression of OVA in dendritic cells does not lead to 
differentiation of Tregs in TCR-transgenic CD4+ T cells. Bone marrow HSCs from OT-II mice were 
transduced with DCSTAMP-trOVA or DCSTAMP-mock lentivirus vector and bone marrow chimeras were 
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generated. After at least 5 weeks of transplantation, chimeras were sacrificed, and cells were analyzed by 
flow cytometry. Splenocytes were gated on CD4+ T cells and CD4+TCRVa2+ T cells were analyzed 
according to their intracellular expression of Foxp3. Total numbers of Foxp3+CD4+TCRVa2+ cells in both 
types of chimeras were compared. At least 3 mice per group were analyzed. 
 
 
5.4 Transgene expression controlled by the DC-STAMP promoter 
leads to tolerance of autoreactive antigen-specific CD8+ T cells.  
 
The study showing that DCs are the main APCs able to delete autoreactive 
CD4+ T cells in the thymus also showed that DCs partake in the process of autoreactive 
CD8+ T cell-deletion (Gallegos and Bevan 2004). To find out whether our system would 
also lead to tolerance of CD8+ T cells, we repeated the same procedure described in 
5.3 using the OT-I mouse strain. This model is similar to the OT-II, except that the CD8+ 
T cells recognize OVA in the context of the MHC-I. As described before in the OT-II 
system, we generated bone marrow chimeras that received HSC transduced with 
DCSTAMP-trOVA- or DCSTAMP-mock-vector. To our surprise, in contrast to what has 
been observed in the OT-II system, we detected no decrease in the frequency of OT-I 
cells in the thymus of our chimeras (Fig. 12a), despite the presence of OVA expression 
in DCs present in the thymus as confirmed by RT-PCR (Fig. 12b). However, after 
analyzing more carefully the CD8 single positive cells in this organ, we detected a slight 
increase in the expression of CD24 among the TCR Vb5+ cells (Fig. 12a, right). As 
CD24 expression is an indicator of T cell maturity, we speculate that despite no 
reduction in the number of OT-I cells, there is perhaps a qualitative difference in these 
cells already in the thymus, predisposing them to the deletion process in the periphery. 
One possible explanation for the observed lack in central deletion of OT-I cells in the 
OVA-expressing chimeras could be that due to the experimental procedure of 
generating BM chimeras, contaminating mature OT-I cells were transferred together 
with the reconstituting BM. OT-I cells might recognize OVA-expressing DCs and kill 
them before they could induce tolerance. It is known that T cells transferred together 
with BM can recognize and mount an immune response against tissue/cells of the BM 
recipients (Sprangers, Van Wijmeersch et al. 2007). In this case, the expression of OVA 
could reflect DCs that didn’t interact with mature OT-I T cells. To pursue the hypothesis 
that absence of central tolerance was due to the presence of such mature T cells, we 
repeated the same procedure as described above, but with CD8+ T cell-depleted OT-I 
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donor BM. In this case, we detected a significant reduction in the frequency of mature 
CD8+ thymocytes (Fig. 12c left, p=0.021, Students t-test). Further analysis revealed that 
significantly fewer CD8 thymocytes were of the OT-I phenotype TCRVa2+Vß5+ in DC-
STAMP-trOVA-chimeras as compared to mock-chimeras (Fig. 12c, p=0.004, Students t-
test). This resulted in a nearly 4-fold reduction of total OT-I thymocyte numbers (Fig. 
12c, right). Compared to the results obtained with the OT-II chimeras (Fig. 9), central 
deletion of CD8+ T cells was less efficient, although all chimeras were generated with 
identical viral titers.  
 
 
 
Figure 12: OVA-expressing dendritic cells induce antigen-specific central deletion of TCR-
transgenic CD8+ T cells. CD8+ T cell non-depleted (a and b) and depleted (c) bone marrow HSCs 
from OT-I mice were transduced with DCSTAMP-trOVA or DCSTAMP-mock lentivirus vector and 
a 
b 
c 
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bone marrow chimeras were generated. After at least 5 weeks of transplantation, mice were 
sacrificed and cells analyzed by flow cytometry. (a and c) Identification of OT-I cells was performed 
according to expression of CD8, TCRVα2 and TCRVß5 as indicated by gates and quadrants. Total 
numbers of thymocytes and total numbers of OT-I T cells were determined (**p=0.004, Student’s t 
test). (b) CD11c-positive and -negative thymic cells were purified by magnetic bead sorting and RNA 
was isolated. RT-PCR analysis from these samples shows the presence of OVA-mRNA only in the 
CD11c-positive fraction, as identified by amplification of a 317 bp-fragment for trOVA. A 302bp-
fragment for ß-actin served as a control. 
 
 
When the peripheral lymphoid organs of both CD8+ T cell-depleted or 
non-depleted BM recipient mice were analyzed, we consistently detected a reduction in 
the OT-I cell compartment, although the reduction was more accentuated in the CD8+ T 
cell depleted chimeras, probably reflecting the combined central and peripheral 
tolerance induced in this group (Fig. 13). In the chimeras that received non-depleted 
DCSTAMP-trOVA transduced BM we observed approximately a 3-fold reduction of 
CD8+ T cell frequencies in the spleen (Fig. 13a, p=0.01, Students t-test). Of those, circa 
26% were of the OT-I phenotype (TCRVa2+Vß5+), compared to 76% in mock chimeras 
(Fig.13a, p=0.0001, Students t-test). Regarding the chimeras that received CD8 T cells 
depleted BM, a nearly 6-fold reduction of CD8+ T cell frequencies in the spleen was 
observed (Fig. 13b left, p=0.009, Students t-test). Of those, only 14%, as compared to 
>80% in mock chimeras, were of the OT-I phenotype (Fig. 13b, p=0.0001, Students t-
test). Together, this resulted in a 50-fold reduction of absolute OT-I T cell numbers as 
compared to control chimeras (Fig. 13b, right).  
The remaining peripheral OT-I T cells were phenotypically equivalent in 
mice receiving either CD8+ T cells depleted or not-depleted BM. Here they displayed 
elevated levels of CD69, CD44, and reduced CD62L expression as evidence of T cell 
activation or Ag-experience (Fig. 13c). However, in contrast to OT-II T cells (Fig. 10b), 
CD25 expression was not modulated (Fig. 13c). This data suggest that tolerance 
induced by Ag-expressing DCs leads to a strong reduction of Ag-specific CD8+ T cells. 
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Figure 13: OVA-expressing dendritic cells induce/maintain tolerance of TCR-transgenic CD8+ T 
cells. CD8+ T cell non-depleted (a) or depleted (b) bone marrow HSCs from OT-I mice were transduced 
with DCSTAMP-trOVA or DCSTAMP-mock lentivirus vector, and bone marrow chimeras were generated. 
After at least 5 weeks post-transplantation, mice were sacrificed and cells analyzed by flow cytometry. (a 
and b) Identification of OT-I cells according to expression of CD8, TCRVα2 and TCRVß5 as indicated by 
gates and quadrants. Total numbers of splenocytes and total numbers of OT-I T cells of both types of 
chimeras were compared in CD8+ T cell non-depleted and depleted BM recipients (***p≤0.0002; 
Student’s t test). (c) OT-I T cells from spleens of chimeras that were reconstituted with CD8+ T cells 
depleted and non-depleted BM were identified as shown in (a and b) and expression of the indicated 
surface molecules was analyzed in DCSTAMP-trOVA- (open histogram) and mock (grey histogram) -
chimeras. At least 3 mice per group were used. 
a 
b 
c 
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As more OT-I T cells were persisting in peripheral organs (Fig. 13) as 
compared to OT-II T cells (Fig. 10), we were able to isolate sufficient numbers of cells to 
analyze their function. To determine whether these non-deleted OT-I T cells from OVA-
expressing chimeras could differentiate into effector T cells and exert autoimmune 
aggression in vivo, the RIP-Ovalo mouse model was used. In this strain, transgenic 
OVA-expression in the pancreas is controlled by the rat insulin promoter (RIP) and 
serves as a model self-Ag (Kurts, Sutherland et al. 1999). When OT-I T cells are 
transferred into RIP-Ovalo mice, they are ignorant due to low expression levels of OVA. 
However, upon Ag-specific immunization, transferred OT-I T cells may become 
activated, destroy the OVA+ pancreatic ß-islet cells and the mice develop diabetes. 
Upon transfer into these recipients, RIP-OVAlo mice were immunized with OVA and all 
mice that received OT-I T cells from mock-chimeras or wild type OT-I donors developed 
diabetes with a similar kinetics (Fig. 14). In marked contrast, none of the mice receiving 
OT-I cells from the CD8+ T cell non-depleted DCSTAMP-trOVA-chimeras developed 
disease (Fig. 14). These results indicate that lentiviral vector-mediated expression of 
OVA in DCs was able to functionally and efficiently inactivate Ag-specific CD8+ T cells, 
even if only peripheral tolerance was induced. 
 
 
 
Figure 14: Lentiviral vector mediated targeting of Ag-expression to dendritic cells generates 
functionally inactivated CD8+ T cells. RIP-OVAlo mice received 1x106 OT-I T cells from DCSTAMP-
trOVA chimeras, mock chimeras or normal OT-I mice. One day later, mice were immunized with either 
OVA-IgG antibody immune-complexes and CpG nucleotides (filled symbols) or CpG nucleotides alone 
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(open symbols). Diabetes induction was monitored and mice with >5,6 nmol/l glucose in their urine were 
considered diabetic. The percentage of diabetic mice over time is shown, n=3-5 mice per group. 
 
 
5.5 Transgene expression controlled by the DC-STAMP promoter 
leads to tolerance of auto-reactive polyclonal antigen-specific CD8+ T 
cells. 
 
In a non-transgenic system with a polyclonal T cell repertoire, only few cells 
express TCRs that recognize a specific antigen, while it is estimated that potentially 
1016 different TCRs can be generated (Abbas and Lichtman, 2003). In addition to these 
numerical differences, in TCR transgenic mice the TCR can be expressed at an earlier 
stage of thymocyte development influencing T cell selection (Baldwin, Sandau et al. 
2005).  
To determine if lentiviral-mediated transgene expression in DCs is able to 
induce tolerance in normal non-transgenic mice, we repeated the described procedure 
using C57BL/6 mice as BM donors and recipients. To evaluate if the polyclonal CD8+ T 
cell repertoire was tolerant to OVA we immunized chimeric mice with a recombinant 
herpes simplex virus vector (HSV) encoding OVA (HSV-OVA), previously reported to 
induce strong OVA-specific CD8+ T cell response (Lauterbach, Kerksiek et al. 2004). 
The frequency of OVA257-264 specific CD8+ T cells and HSV glycoprotein B (HSVgB) 
specific CD8+ T cells was determined by H-2Kb/OVA257-264 and H-2Kb/HSVgB498-505 
tetramer-staining respectively, at day 7 after immunization (Fig.15). While we saw 
significantly higher frequencies of OVA-tetramer positive CD8 T cells in mock chimeras 
than in DCSTAMP-trOVA chimeras, no reduction was found in the frequency of control 
HSVgB-tetramer positive CD8 T cells. The increased frequencies of HSVgB-tetramer 
positive CD8 T cells in DCSTAMP-trOVA chimeras could possibly reflect compensatory 
expansion resulting from the absence (or decrease) of interclonal competition with 
OVA-specific T cells. These results indicate that as observed in the transgenic OT-I 
system, also in a normal polyclonal repertoire there was a decrease in the amount of 
peripheral OVA reactive CD8+ T cells. Moreover, in this system it was also possible to 
address directly the specificity of the tolerance induction, which is not feasible in a TCR-
transgenic model. 
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Figure 15: Antigen expression in dendritic cells induces Ag-specific depletion of CD8+ T cells in a 
polyclonal repertoire. Bone marrow HSCs from C57Bl/6 mice were transduced with DCSTAMP-trOVA 
or DCSTAMP-mock lentivirus vectors, and bone marrow chimeras were generated. After at least 10 
weeks following transplantation, chimeras were immunized by i.v. injection of 4x106 pfu of recombinant 
HSV expressing OVA. 7 days after immunization, leukocytes were isolated from peripheral blood of 
DCSTAMP-trOVA or mock chimeras and stained with antibodies specific for CD8 (not shown), CD62L as 
well as H2Kb-OVA- or H2Kb-HSVgB-tetramers, and the frequencies of H-2Kb/OVA or H-2Kb/HSV-specific 
cells among all CD8+ T cells were analyzed by flow cytometry. N=2-4 mice per group.  
 
To address the question whether or not OVA-specific CTL were present 
but below the detection limit of MHC-tetramer staining, we performed a highly sensitive 
in vivo killer assay and determined the percentage of specific cytolysis. This technique 
is based on the ratio of specific elimination of peptide-loaded spleen cells labeled with a 
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high concentration of CFSE over unloaded-control cells labeled with low concentration 
of CFSE. Consistent with the results obtained by the tetramer staining, DCSTAMP-
trOVA chimeras were not able to perform significant lysis of OVA257-264 loaded target 
cells, while the mock chimeras were able to kill approximately 90% of all OVA257-264 
loaded target cells (Fig. 16). As both mock and DCSTAMP-trOVA chimeras were 
equally efficient in killing of HSVgB498-505 loaded cells (Fig. 16), we conclude that 
tolerance induction was Ag-specific. The results obtained with these experiments 
strongly suggest that transcriptional targeting of DCs with this lentivirus vector induces 
Ag-specific tolerance of CD8+ T cells also in a normal non-transgenic polyclonal system. 
 
 
 
Figure 16: Antigen expression in dendritic cells induces Ag-specific functional tolerance of CD8+ 
T cells in a polyclonal repertoire. Bone marrow HSCs from C57Bl/6 mice were transduced with 
DCSTAMP-trOVA or DCSTAMP-mock lentivirus vectors and bone marrow chimeras were generated. 
After at least 10 weeks following transplantation, chimeras were immunized by i.v. injection of 4x106 pfu 
of recombinant HSV vector expressing OVA. On day 7 after immunization, a CFSE- based in vivo 
cytotoxic T cell assay was performed, and the specific lysis of OVA-SIINFEKL or HSVgB-SSIEFARL 
peptide loaded, CFSE-labeled target cells was determined by flow cytometry. N=2-4 mice per group. 
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5.6 The murine DC-STAMP promoter directs transgene expression in 
human DCs in vitro.  
 
As it was described previously that DC-STAMP protein is highly 
conserved between human and mice and that its expression is basically restricted to 
DCs in both species, we hypothesized that the murine DC-STAMP promoter could also 
direct transgene expression specifically in human DCs. To answer this question, we 
used the Genomatix software to perform a computational comparison of the 3’ UTR of 
the DC-STAMP promoter from mouse, human and dog, looking for conserved binding 
site modules in the three species. It is difficult to discriminate significant single 
transcription binding site elements important for promoter specificity. Common 
framework elements where more than one element is found in the same order and 
distance range in inter-species analysis are much more indicative, since it is known that 
there may exist a synergistic effect among transcription binding sites, and that the 
conservation of their sequential order is important to keep transcription specific to a 
certain cell type (Fig. 17; Werner 1999). Furthermore, since several proteins must 
interact with any given promoter to activate transcription (Thanos and Maniatis 1995), a 
set of binding sites instead of individual ones should be analyzed. As shown in Fig. 17, 
we were able to identify a conserved region (p-value of 4.79e-11, where the p-value is 
the probability to obtain the same model in a randomly drawn sample of human 
promoters), comprising 4 different elements in the same order of sequence around -
1.5Kb in mouse and dog and around -2 kb in human DC-STAMP promoter, indicating a 
potential group of elements that could partake in the control of specificity of gene 
expression.  
 
Figure 17: The DC-STAMP promoter is conserved among different species. Around 2 kb (human) 
and 1.5 kb (mouse and dog) of 5’ UTR from DC-STAMP promoter sequence was obtained from 
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GeneBank database (http://www.ncbi.nlm.nih.gov/Genbank/index.html), and computational comparison 
was performed using the Genomatix software (www.genomatix.de/). Schematic representation of 
regulatory element comparison of DC-STAMP promoter from human, mouse and dog, where +1 is the 
transcriptional start site.  
 
 
To test if the murine DC-STAMP promoter would also drive transgene 
expression in human DCs, we transduced mono nuclear cells (MNC) isolated from 
human BM with our vector containing the eGFP driven by the murine DC-STAMP 
promoter or by the constitutively active human ubiquitin-C promoter (ubiquitin-eGFP). 
Transduction with DCSTAMP-GFP-SIN-lentivirus resulted in higher DC-specificity as 
compared to the ubiquitin-GFP-SIN-lentivirus (Fig. 18). A ratio of ∼3 was obtained for 
GFP+CD1a+ DC and GFP+CD1a- non-DC for DC-STAMP-transduced DCs as compared 
to a ratio of 1 for DC transduced with the ubiquitin-C promoter containing lentiviral 
vector (Fig. 18). Accordingly, also fewer CD14+ monocytes and CD19+ B lymphocytes 
expressed eGFP in DCSTAMP-lentivirus transduced cultures (Fig. 18). This preliminary 
data indicates that the murine DC-STAMP promoter used in the SIN-lentivirus vector 
context supports expression of transgenes also in human DCs. 
 
 
 
Figure 18: The murine DC-STAMP promoter targets expression to human dendritic cells in vitro. 
Human bone marrow was cultured with GM-CSF, IL-4 and TNF-α and, at day 2 of culture, cells were 
transduced with DCSTAMP-eGFP, ubiquitin-eGFP or DC-STAMP mock lentivirus vector. Flow cytometry 
was performed at day 11 of culture with the indicated antibodies.  
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6. Discussion 
 
6.1 The murine DC-STAMP promoter targets transgene 
expression to DCs  
 
There are several transgenic mice that express different molecules 
selectively in DCs. These mice have been very helpful in elucidating the functional 
differences among the APCs and especially the role of DCs in the immune system. All 
transgenic mice with DC-specific expression were generated using the murine CD11c 
promoter (Brocker, Riedinger et al. 1997). In principle, murine CD11c is expressed only 
in DCs and in all main sub-populations of DCs, although with different levels of 
expression depending on the type of DC. Generally, CD11c is considered a myeloid 
marker and possibly for this reason, its expression in pDCs can be very low. Indeed, it 
was described that in transgenic mice in which cDNA expression was driven by the 
CD11c promoter, little or no transgene expression could be detected in pDCs 
(Sapoznikov, Fischer et al. 2007). For this reason, we decided to test an alternative 
promoter that could potentially target all DC sub-populations and states of maturation. 
These characteristics, among others, led us to choose the DC-STAMP promoter. In 
addition, because the generation of transgenic mice is a time consuming and expensive 
process, our aim was to develop a viral system which could allow stable transgene 
expression in DCs without the need to produce transgenic mice. Moreover, when 
considering the targeting of DCs for future clinical applications, it is of fundamental 
importance to choose a system which can also be used in humans, such as retro or 
lentiviral vectors. In the present study, we developed a lentiviral vector that targets 
transgene expression mainly to DCs. In addition to confering murine DC-selective 
transgene expression, this system seems to be promissory for targeting human DCs. 
 
 
6.1.1 A SIN-lentiviral but not retroviral vector allows specific 
transgene expression in DCs 
 
In both basic research and clinical applications, there are several 
instances in which a methodology that allows stable instead of transient transgene 
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expression by DCs would be advantageous. Taking this prerequisite under 
consideration, we believe that either retro- or lentiviral vectors could lead to satisfactory 
results, since both vectors can integrate into the genome of the infected cell, leading to 
stable transgene expression. Our aim was to transduce BM-derived HSCs and 
repopulate irradiated recipient mice with these cells. This would result in reconstitution 
of the immune system with the transduced HSC derived cells, but with transgene 
expression only in DCs. When cell-specific promoters are placed into a retro- or 
lentiviral vector, it is essential to use SIN virus vector backbones in order to gain cell-
specificity. It was shown in independent studies that the native viral promoter elements 
can interact with the internal promoter, reducing gene expression (Yee, Moores et al. 
1987; Soriano, Friedrich et al. 1991). However, one important restriction of SIN 
retroviruses is the reduced virus titer obtained (Riviere, Brose et al. 1995; Vile, Diaz et 
al. 1995). 
In principle, only lentivirus, but not retrovirus can efficiently infect HSCs, 
since these cells are known to be quiescent and only lentivirus have the ability to infect 
cells in a non-proliferative state. However, retroviral vectors were used successfully 
before in our laboratory to transduce BM derived HSCs with the objective of targeting 
transgene expression to B cells (Werner, Kraunus et al. 2004; Werner-Klein, Dresch et 
al. 2007). These previous results encouraged us to use the same retroviral vector 
backbone to transcriptionally target DCs. The first drawback we faced with the use of 
this retroviral system was the low viral titers obtained (Fig. 5). This was probably due to 
the fact that our vector was a SIN vector, and that the size of the promoter used to 
target DCs was considerably large. In fact, the small transgene capacity of retro- and 
lentiviral vectors (limit of 7-8 kb) is a major limitation for their use in gene therapy. In the 
work using the retroviral vector to drive transgene expression in B cells, the promoter 
used was approximately 700 bp shorter than the DC-STAMP promoter used in our 
work. This difference in size may have allowed the production of higher virus titers. 
Although the transgene capacity of retroviruses and lentiviruses is the same, the 
negative effect of the deletion of the regulatory sequences in the U3 region responsible 
for conferring the SIN characteristics is not the same for the two vectors. Low titers from 
SIN vectors are associated only with retro but not lentiviral vectors (Yee JK, 1987; 
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Zufferey R, 1998), which could explain the low titers obtained from the retrovirus vector 
production when compared to the lentivirus vector production (Fig. 5). 
 As there is no published work showing a DC-specific promoter in the 
context of a viral vector, we decided to test both retro and lentiviral vectors in an in vivo 
approach. Surprisingly, we obtained different results from the two vectors although they 
contained the same fragment of the DC-STAMP promoter. While the DC-STAMP 
promoter in the context of the SIN-retrovirus could render only weak basal transgene 
expression in the different cells of the immune system, the same promoter when in the 
context of the SIN-lentivirus vector resulted in transgene expression mainly in DCs (Fig. 
6 and 7). Although to our knowledge there is no work where the same tissue-specific 
promoter was compared side by side in the context of a retro and a lentiviral vector, we 
suggest that the nature of the HSCs transduced with the viral vectors may be 
responsible for these results. HSCs are constantly choosing between a state of 
quiescence, self-renewal and lineage differentiation, where self-renewal can be only 
maintained in an appropriate microenvironment in distinct locations within the BM (Arai, 
Hirao et al. 2005). HSCs can be classified in three major categories according to 
functional hierarchies. The most undifferentiated would be the quiescent HSCs 
(0.00125% of BM cells), followed by activated or self-renewing HSCs (0.00425% of BM 
cells) and differentiating HSCs (0.3% of BM cells) (Wilson, Oser et al. 2007). Several 
groups have analyzed the potential of long-term reconstitution of HSCs at different 
states of “maturation”, and it is currently believed that the dormant and activated cells 
would retain the highest repopulating capacity (Kiel, Yilmaz et al. 2005). Since special 
BM niches are required to HSC self-renewal (Huang, Cho et al. 2007), and 
consequently it is not possible to keep these cells in culture, the quiescent HSCs would 
probably be the main subset of HSCs that reconstitute the hematopoietic system after 
BM transplantation. Therefore, it is possible that we were able to observe DC-specific 
transgene expression only when quiescent HSCs were modified. The fact that only 
lenti- but not retroviral vectors are able to infect quiescent cells would explain the 
different results obtained with the two vectors. The branching points at which 
hematopoietically derived cell lineage commitment occurs is still controversial (Akashi 
2007; Iwasaki and Akashi 2007), and little is known about the early regulation of gene 
expression and silencing during the initial stages of cell differentiation. However, it is 
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known that pluripotency as well as lineage differentiation depend upon specific 
chromatin organization, which is required for establishing and maintaining gene 
expression programs (Teitell and Mikkola 2006). We therefore suggest that at a later 
differentiation point, the DC-STAMP promoter could be silenced, resulting in only a low 
background of transgene expression. However, such a phenomenon was not observed 
with the CD19 promoter, which supported transgene expression in B cells, even if HSCs 
from a late state of differentiation were infected with standard retrovirus vectors. While 
we can only hypothesize about the factors influencing transgene expression with 
different kinds of viral vectors, we clearly showed (Figs. 6 and 7) that the DC-STAMP 
promoter can efficiently target transgene expression to DCs in vivo in the context of a 
SIN-lentiviral but not SIN-retroviral vector. 
 
 
6.1.2 The DC-STAMP promoter drives transgene expression mainly in 
DCs 
 
Although DC-STAMP was originally isolated from a cDNA library of 
human monocyte–derived dendritic cells (Hartgers, Vissers et al. 2000), recent studies 
have clearly shown its expression and function in osteoclasts (in the bone) and giant 
cells [in different tissues; (Kukita, Wada et al. 2004; Vignery 2005)]. Osteoclasts and 
giant cells are multinucleated cells originating from the fusion of macrophages, although 
the mechanisms that govern this process are poorly understood. In fact, the 
monocyte/macrophage lineage is quite heterogeneous and it is believed that such 
heterogeneity is physiologically relevant, since it is conserved in human and mouse 
(Gordon and Taylor 2005).  
While it is clear that monocytes can give rise to different specialized 
cells, further studies are necessary to understand for example how monocytes are 
recruited to particular sites of inflammation and what determines their differentiation into 
DCs or into macrophages. By using our lentiviral vector with transcriptional control by 
the DC-STAMP-promoter, we were able to transduce HSCs and obtain transgene 
expression mainly in DCs, but also in some monocytes (Fig. 6 and 7). In the present 
study we identified monocytes as CD11b+CD11c- cells. Although it is known that 
monocytes are progenitors of at least some subpopulations of DCs, the differentiation 
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pathways have not yet been identified (Gordon and Taylor 2005), and it is difficult to 
differentiate between “real” monocytes and DC-precursors. But as DC-STAMP is a 
protein expressed in cells originating from monocytes, it is not surprising that some 
transgene expression driven by the DC-STAMP promoter was also detected in this type 
of cells. Nevertheless, since the monocyte lineage is closely related to DCs, there are 
few, if any, negative implications that could possibly arise from transgene expression in 
both monocytes and DCs. Interestingly, although transgene expression in DCs and 
monocytes points towards a preferencial activity of the DC-STAMP promoter in myeloid 
cells, we also observed a high expression of the reporter transgene in the CD8+ DC 
population, which has been described as being of lymphoid origin (Ardavin 2003). In 
contrast, pDCs that are also considered as predominantly of lymphoid origin expressed 
DC-STAMP-transgene only weakly in most experiments (Fig. 7a). Therefore, the 
lentiviral DC-STAMP system may be a valuable tool also to study DC origin and 
development.  
 As DC-STAMP is a protein that was originally identified in human DCs 
(Hartgers, Vissers et al. 2000), it would be expected that its promoter would also be 
efficient in targeting DCs from human origin. When we compared transgene expression 
regulated by DC-STAMP promoter and an unspecific ubiquitous promoter, we showed 
that DC-STAMP was more efficient to target transgene expression in DCs (Fig. 18). 
Therefore, our preliminary results in vitro indicated that the DC-STAMP-lentivirus might 
be promising for targeting human DCs. However, further studies will be required to 
demonstrate its DC-specificity in human hematopoietic systems. 
 
 
6.2 DC-STAMP-lentivirus mediated transgene expression 
induces antigen-specific tolerance in CD4+ and CD8+ T cells 
in vivo  
 
Although T cells expressing a TCR with high affinity for self-antigens are 
mainly deleted in the thymus, it is unlikely that the deletion of all autoreactive T cells 
occurs exclusively there. To control autoreactive T cells that have escaped negative 
selection in the thymus, peripheral tolerance is an important mechanism to complement 
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central tolerance (Mathis and Benoist 2004). DCs play a central role in maintaining both 
central and peripheral tolerance by inducing clonal deletion or non-responsiveness. 
Antigen presentation by DCs was shown to be important in tolerance induction in 
transgenic murine models (Gallegos and Bevan 2004) and targeting DCs with specific 
antibodies (Gunzer, Weishaupt et al. 2004) or DC-specific promoters (Probst, Lagnel et 
al. 2003; Probst, McCoy et al. 2005) results in tolerance to the corresponding antigen. 
The activation state of the DCs that present self-antigens is pivotal to the outcome of T 
cell activation. When DCs are activated T cell priming occurs and when resting DCs 
present the antigen T cell tolerance takes place (Banchereau and Steinman 1998; 
Hawiger, Inaba et al. 2001; Steinman, Hawiger et al. 2003). Since DCs are implicated in 
induction and maintenance of T cell tolerance, we wanted to investigate if our lentiviral 
vector system could be applied for antigen-specific tolerance induction. 
In this study we were able to show that lentiviral vector-mediated 
expression of a transgene by DCs induces central tolerance of antigen-specific CD4+ T 
cells (Fig. 9). While the importance of DCs in inducing central tolerance of CD4+ T cells 
is well accepted, the consensus about participation of DCs in generation of natural 
Foxp3+CD25+ Tregs is more conflicting. While it is widely accepted that natural Treg 
cells originate in the thymus as a functionally distinct and mature population, there is 
evidence that T cells with similar immune suppressive activity can be generated from 
naïve T cells in the periphery after, for example, chronic antigen stimulation in vivo 
(Chen, Jin et al. 2003; Apostolou and von Boehmer 2004). As we analyzed all BM 
chimeras only in steady state but not under infection or inflammatory conditions, the 
question if lentiviral vector-mediated expression of antigen by DCs would lead to 
peripheral Treg differentiation requires further analysis.  
In addition, the exact nature of the antigen-expressing and/or antigen-
presenting cells involved in natural Treg cell development within the thymus is 
unknown. An in vitro study with human thymus suggested that thymic DCs conditioned 
with thymic stromal lymphopoietin may promote the generation of Treg cells in the 
human thymus (Watanabe, Wang et al. 2005). More recently it was shown that antigen 
specific presentation by DCs led to deletion of autoreactive CD4+ T cells in the thymus, 
while antigen presentation by thymic epithelial cells would lead to the differentiation of 
natural Treg (Aschenbrenner, D'Cruz et al. 2007). Moreover, in the same study it was 
   
 77 
suggested that DCs are not able to delete CD4+ T cells that were already differentiated 
into Treg. These findings are in accordance with our preliminary results, in which no 
difference could be observed in total numbers of Foxp3+CD25+ Treg cells between mock 
and SIN-DC-STAMP-trOVA chimeras (Fig.11). These results indicate that lentiviral 
vector-mediated expression of transgene by DCs leads to central tolerance of CD4+ T 
cells by depleting autoreactive cells, but not by inducing differentiation of these cells into 
natural Treg cells.  
 Although we showed that lentiviral vector-mediated expression of the 
transgene by DCs was sufficient for inducing central tolerance of both autoreactive 
CD4+ and CD8+ T cells, central deletion of Ag-specific CD8+ T cells was less efficient 
(Fig. 9 and 12). These results are in accordance with previous findings showing that 
DCs are preferentially involved in CD4+ T cells central tolerance induction, but that 
mTECs can participate in the deletion of CD8+ T cells (Gallegos and Bevan 2004). 
However, in Gallegos and Bevan’s work not the DCs but the thymic epithelial cells were 
expressing the OVA protein and the DCs were acquiring and cross-presenting the 
peptide. However, the process of cross-presentation or even a possible 
interaction/cooperation between the TECs and DCs may be important for the deletion of 
the autoreactive CD8+ T cells in the thymus. Consequently, the lack of transgene-
expression by TECs in our BM chimeras may result in lower deleting-efficacies of CD8+ 
thymocytes. Nevertheless, Ag-expression in DCs led to a tolerant CD8+ T cell 
compartment. We showed that CD8+ T cells escaping central thymic deletion were 
functionally inactivated, since none of the RIP-OVAlo mice that received OT-I cells from 
our DC-STAMP-trOVA-chimeras developed diabetes (Fig. 14).  
The OT-I and –II TCR-transgenic read-out systems used in this study 
demonstrated that lentiviral targeting of DCs imposed robust tolerance induction even in 
presence of artificially high precursor-frequencies of Ag-specific T cells (Fig. 9, 10, 12 
and 13). However, transgenic TCRs can be expressed at earlier stages of thymocyte-
development as compared to natural endogenous TCR-proteins and this may affect T 
cell selection (Baldwin, Sandau et al. 2005). To exclude the possibility that our system 
would be efficient only in TCR transgenic mice, we repeated the same procedure in wild 
type non-transgenic mice. We found that polyclonal “normal” T cells could also be 
tolerized, as complete absence of Ag-specific CD8+ T cell immunity in peripheral organs 
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was demonstrated (Fig. 15 and 16). Therefore, lentiviral vector-mediated DC-targeting 
seems to induce tolerance also in wild-type T cell populations, although we were not 
able to distinguish in this case if tolerance was imposed centrally or in peripheral organs 
by deletion or anergy.  
 
 
6.2.1 Effect of CD8+ T cell depletion from the donor bone marrow on 
tolerance induction  
 
One interesting observation from our results is the absence of central 
deletion of OT-I cells in the chimeric recipients of BM non-depleted of CD8+ T cells. In 
contrast, in the same chimeras peripheral deletion and tolerance induction of OT-I cells 
occurred (Fig.12 and 13). However, when the CD8+ T cells were depleted from the 
donor bone marrow the amount of OT-I cells was also reduced in thymus, although we 
observed a strong reduction in both percentage and total cell numbers only within 
spleen and LN (Fig. 12, 13 and data not shown). The fact that we could not detect any 
difference in the OT-I cell number or frequency in the thymus of CD8+ T cell non-
depleted BM recipients, suggests a possible donor T cell cytotoxic effect restricted to 
DCs resident in the thymus, but not in the peripheral lymphoid organs. This cytotoxity 
could lead to killing of DCs presenting OVA antigen, although OVA RNA could be 
detected in the DC+ fraction of cells isolated from thymus (Fig. 12b).  
In addition, it was possible to detect an increase in expression of CD24 
in the OT-I cells in the thymus of SIN-DC-STAMP-trOVA chimeras compared to mock 
chimeras (Fig.10a), indicating an immature state of these cells. Together, these results 
suggest that even if killing of OVA presenting DCs occurred, OT-I cells might have had 
contact with at least some DCs. This interaction was not sufficient for depletion of 
autoreactive CD8+ T cells, but may have been sufficient to lead these cells to a 
functional and/or qualitative change. Therefore, although no difference in total numbers 
of OT-I cells was detected, it remains possible that the OT-I cells were qualitatively 
different and left the thymus with a “predisposition” to be tolerized. Indeed it has 
previously been discussed that tolerance to host class I antigens is more marked in LN 
than in thymus, and that auto-reactive CD8+ T cells could be rendered “semi-tolerant” in 
the thymus to have the complete process of tolerization taking place in peripheral 
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lymphoid organs (Sprent, Kosaka et al. 1993). In accordance with this idea, it was 
shown that CD8+T cells isolated from the thymus of chimeras give significant 
proliferative responses to host-type Ags when stimulated in vitro, while cells isolated 
from LN and spleen gave extremely low responses under the same conditions (Kosaka 
and Sprent 1993). This would also be in consistent with our results regarding CD8+T cell 
depleted BM recipients, where tolerance induction was much more efficient in the 
periphery than in the thymus. 
It is also possible that the kind of interaction and signaling between DCs and T 
cells in the thymus is different as compared to T cell signaling in secondary lymphoid 
organs. Such differences could allow killing of thymic DCs. Indeed, thymic DCs have 
some particularities when compared with the peripheral counterparts. The majority 
(75% in B6 and 90% in Balb/c) of DCs in thymus are CD8+ (Vremec, Pooley et al. 
2000). Moreover, the great part of the thymic CD8+ DCs are different as compared to 
CD8+ DCs found in the periphery. A proportion of thymic CD8+ DCs, but not of 
peripheral DCs, express mRNA and surface BP-1 [a glycoprotein mainly expressed by 
early B cells; (Wu, Vremec et al. 1995; Okada, Lian et al. 2003)]. These particularities 
are in agreement with the different origin of thymic and peripheral DCs. Currently it is 
believed that the major thymic DCs are generated within the thymus (Ardavin, Wu et al. 
1993). Furthermore, many CD8+ thymic DCs have a more “activated” state than their 
peripheral counterparts, since the co-stimulatory molecules CD80 and CD86 are 
expressed at higher levels (Wilson, El-Sukkari et al. 2003). This more activated state 
could also explain why mature donor OT-I cells could kill DCs in the thymus but not 
those found in the periphery. However, further studies are necessary to address these 
questions directly. 
 
 
6.3 Therapeutic potential of gene therapy for tolerance 
induction by a DC-specific lentiviral vector  
 
Gene-therapy is considered an efficient method to induce tolerance, 
when the identity of target-Ags in autoimmune diseases and transplant rejections are 
known, and several studies on this topic have been published (Ally, Hawley et al. 1995; 
Kang, Melo et al. 1999; Tsokos and Nepom 2000; Bagley, Tian et al. 2002; Kang and 
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Iacomini 2002; Tian, Bagley et al. 2003). However, in these studies tolerance induction 
was achieved with conventional retroviral vectors leading to transgene expression in 
multiple cell-types. This can be accompanied by potentially dangerous activities of viral 
enhancers (Li, Modlich et al. 2004), as vector integration in the proximity of a proto-
oncogene promoter could induce uncontrolled exponential clonal cell proliferation. The 
development of T-cell leukemia in three out of 20 patients following gene-therapy for the 
treatment of X-linked severe combined immune deficiency (X-SCID) has highlighted the 
adverse effect of insertional mutagenesis and led to a re-evaluation of this approach 
(Hacein-Bey-Abina, Von Kalle et al. 2003; Marshall 2003; Check 2005). The gene 
IL2RG encodes the gamma-chain of the interleukin-2 receptor and is mutated in 
patients with X-SCID. It has been shown that retroviral integration of the corrective 
IL2RG occurred near the locus of the LMO2 oncogene5 and that this integration may 
have upregulated the expression of LMO2 and, eventually, led to leukemia in 3 gene 
therapy patients (Hacein-Bey-Abina, Von Kalle et al. 2003). The possibility that IL2RG 
might itself be a contributor to oncogenesis raised again the value of gene therapy. In a 
recent study, it was shown that 33% of C57BL6 X-SCID mice developed T-cell 
lymphomas after reconstitution with X-SCID or wild-type bone-marrow stem cells 
transduced with lentiviral vectors encoding IL2RG. However, X-SCID mice engrafted 
with bone-marrow cells treated by mock transduction, did not develop lymphomas. As 
there were no common genomic targets in the five mice with lymphoma and because 
the controls did not develop disease, the authors concluded that the lymphomas were 
not caused by insertional mutagenesis and that the therapeutic transgene itself is 
intrinsically oncogenic (Woods, Bottero et al. 2006). In accordance with the idea that not 
the virus per se is responsible for cancer development, is the fact that HIV+ patients do 
not have an increased frequency of cancers that could be correlated with insertional 
mutagenesis. A higher incidence of cancer in AIDS patients has been reported, but this 
has been correlated rather with immunosupression than viral insertion (Grulich, van 
Leeuwen et al. 2007). These new findings are causing researchers to reconsider gene 
therapy with a more optimistic view. 
Despite this, the random insertion of the viral vector into the genome 
and its potential risks are still a negative characteristic of gene therapy, and approaches 
to reduce these risks are necessary. For example, the use of lentiviral vectors equipped 
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with an appropriate eukaryotic promoter and without viral enhancers can minimize 
potential dangers. The approach presented in this work was to target transgene 
expression to DCs, a cell type present only in low numbers with a low propensity for 
proliferative disorders. In addition, DCs are the functionally most relevant and efficient 
cell-type for immune modulations such as tolerance induction. Several reports describe 
in vitro modifications of human DCs for boosting immune responses against cancer 
(Schuler, Schuler-Thurner et al. 2003) or induction of tolerance (Dhodapkar, Steinman 
et al. 2001; Dhodapkar and Steinman 2002). The major drawbacks of these studies 
included the difficulties to obtain sufficient amounts of DCs for application, functional 
DC-changes by their ex vivo manipulation, as well as influences of the route of DC-
application on the experimental outcome (Fong, Brockstedt et al. 2001). Moreover, 
whether antigen-pulsed DCs induce autoimmunity or tolerance is still controversial. For 
example, DCs have been described to induce experimental autoimmune 
encephalomyelitis [EAE, (Weir, Nicolson et al. 2002)] and diabetes (Ludewig, Odermatt 
et al. 1998) in mice. However, DCs have also been reported to mediate protection 
against the same diseases (Huang, Yang et al. 2000; Papaccio, Nicoletti et al. 2000). 
Indeed, adoptive transfer of spleen-derived DCs from mobilized donor mice failed to 
confer protection from GVHD (MacDonald, Rowe et al. 2005), a result that has been 
attributed to an inadequate state of DC maturation. Approaches involving the genetic 
modifications of DCs are mostly based on the viral transduction of genes encoding 
immunosuppressive molecules, such as CD95 (Fas) ligand, IL-10 and CTLA4 
(Takayama, Nishioka et al. 1998; Takayama, Morelli et al. 2000; Buonocore, Van 
Meirvenne et al. 2002; Buonocore, Paulart et al. 2003). Whereas the in vitro 
immunosuppressive efficacy of such modified DCs is unquestionable, its in vivo effect is 
not guaranteed. A possible explanation for this is that ex vivo manipulation and virus 
vector transduction induce DC maturation and activation (Miller, Lahrs et al. 2002). 
However, the maturation state of DCs does not seem to be the only factor influencing T 
cell responses. Recent studies show that fully mature DCs can be tolerogenic (Albert, 
Jegathesan et al. 2001). Cross-tolerance of Ag specific CD8+ T cells requires DCs with 
a mature phenotype (Albert, Jegathesan et al. 2001). This raises the question which DC 
maturation process can induce tolerance.  
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Further, a general restriction of adoptive DC-transfer is the limited 
survival of cultured DCs in vivo, making several consecutive therapeutic interventions 
necessary to obtain measurable DC-induced immune modulation. Induction of CD8+ T 
cell tolerance depends on long-term exposure of T cells to Ag-presenting DC in vivo 
(Redmond and Sherman 2005). Also in vivo imaging has shown that multiple brief DC-
CD8+ T cell contacts were required over prolonged periods of time for efficient tolerance 
induction (Hugues, Fetler et al. 2004). Therefore, the lentiviral system presented in our 
study would be advantageous as it allows the modification of autologous bone marrow 
for continuous output of genetically modified tolerogenic “steady-state” DCs without the 
need for multiple ex vivo manipulations.  
Through computational analysis we compared the DC-STAMP promoter 
sequence of mouse, human and dog, and found highly conserved regulatory regions 
among the three sequences (Fig. 17). These findings suggest that a DC-STAMP 
promoter could also be used to target DCs in different species. Indeed our preliminary 
results in vitro indicated that the DC-STAMP-lentivirus might be promising for targeting 
human DCs (Fig. 18). However, further studies will be required to demonstrate its DC-
specificity in human hematopoietic systems. 
In the present work, we tested the efficiency of T cell tolerance 
induction by lentiviral vector-mediated transcriptional targeting of DCs. Tolerance 
induction occurred in Ag-specific CD4+ and CD8+ T cell compartments, in both 
transgenic and wild type mice. Taken together, our results provide strong evidence that 
DC-specific lentiviral approaches are a potent means to induce and maintain Ag-
specific CD8+ and CD4+ T cell tolerance and may be of clinical relevance for therapeutic 
applications in a transplantation or autoimmune setting where T cell tolerance is 
required to limit tissue pathology. 
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7. Outlook 
 
In the prophylaxis/treatment of transplantation and autoimmune diseases, standard 
immunosuppressive strategies consist of the inactivation of the whole or large part of 
the immune system. This nonspecific inhibition compromises the ability of the host to 
combat opportunistic infections and/or increase the risk of cancer development. 
Therefore, self Ag-specific tolerance strategies have the best therapeutic potential, 
since they maintain the capacity of the immune system to clear non-self Ags. Several 
clinical trials have been performed to induce antigen-specific tolerance in autoimmune 
diseases such as multiple sclerosis, rheumatoid arthritis and type I diabetes. To date, 
the efficacy of the employed immunotherapies is uncertain, in part because of factors 
such as route, dosage and frequency of antigen administration. Oral administration of 
Ag has been effective in inhibiting the induction of autoimmune disease in animal 
models, however, there is to date no indication of efficacy of this kind of therapy for the 
treatment of autoimmune diseases in humans. Even when the protein involved in the 
development of the autoimmunity is identified, as the myelin basic protein in the case of 
multiple sclerosis, the efficacy of the peptide administrated to induce tolerance can vary 
depending on the HLA of the patient. The diversity of the human HLA haplotype is 
probably one of the factors contributing to the variable results from the so far tested Ag-
specific tolerogenic approaches. Besides being specific and long-lasting, another 
advantage of the lentivirus-mediated tolerance induction presented in this work is that 
the identification of the specific epitope(s) involved in the onset of the autoimmune 
disease (and the correlation of such peptide and specific HLA) is not necessary. The 
DC expresses the whole cDNA of interest, leading to presentation of several different 
epitopes. The same advantage would apply to tolerance induction in case of allergy and 
transplantation. Regarding basic research, the targeted transgene expression by DCs 
through the lentiviral vector presented in this work, will enable the study of questions 
related to the biology of DCs and perhaps the regulation/differences between central 
and peripheral tolerance induction.  
 
 
   
 84 
8. Bibliography 
 
 
Abbas, A., Auchincloss, H., Austen, K.F., Bluestone, J., Carpent, C., Chess, L., Davie, 
J., Fathman, C.G., Howard, M., Kinet, J.P., Kirk, A., Nadler, L., Sykes, M. and 
Turka, L. (1999). Report of the NIAID Expert Panel on Immune Tolerance. .  
. 
Aiuti, A. (2002). "Advances in gene therapy for ADA-deficient SCID." Curr Opin Mol 
Ther 4(5): 515-22. 
Akashi, K. (2007). "Cartography of hematopoietic stem cell commitment dependent 
upon a reporter for transcription factor activation." Ann N Y Acad Sci. 
Albert, M. L., M. Jegathesan, et al. (2001). "Dendritic cell maturation is required for the 
cross-tolerization of CD8+ T cells." Nat Immunol 2(11): 1010-7. 
Ally, B. A., T. S. Hawley, et al. (1995). "Prevention of autoimmune disease by retroviral-
mediated gene therapy." J Immunol 155(11): 5404-8. 
Altschul, S. F., T. L. Madden, et al. (1997). "Gapped BLAST and PSI-BLAST: a new 
generation of protein database search programs." Nucleic Acids Res 25(17): 
3389-402. 
Anderson, M. S., E. S. Venanzi, et al. (2002). "Projection of an immunological self 
shadow within the thymus by the aire protein." Science 298(5597): 1395-401. 
Apostolou, I. and H. von Boehmer (2004). "In vivo instruction of suppressor commitment 
in naive T cells." J Exp Med 199(10): 1401-8. 
Arai, F., A. Hirao, et al. (2005). "Regulation of hematopoietic stem cells by the niche." 
Trends Cardiovasc Med 15(2): 75-9. 
Ardavin, C. (2003). "Origin, precursors and differentiation of mouse dendritic cells." Nat 
Rev Immunol 3(7): 582-90. 
Ardavin, C., L. Wu, et al. (1993). "Thymic dendritic cells and T cells develop 
simultaneously in the thymus from a common precursor population." Nature 
362(6422): 761-3. 
Aschenbrenner, K., L. M. D'Cruz, et al. (2007). "Selection of Foxp3+ regulatory T cells 
specific for self antigen expressed and presented by Aire+ medullary thymic 
epithelial cells." Nat Immunol 8(4): 351-8. 
   
 85 
Asselin-Paturel, C., A. Boonstra, et al. (2001). "Mouse type I IFN-producing cells are 
immature APCs with plasmacytoid morphology." Nat Immunol 2(12): 1144-50. 
Bagley, J., C. Tian, et al. (2002). "T cells mediate resistance to genetically modified 
bone marrow in lethally irradiated recipients." Transplantation 74(10): 1454-60. 
Baldwin, T. A., M. M. Sandau, et al. (2005). "The timing of TCR alpha expression 
critically influences T cell development and selection." J Exp Med 202(1): 111-21. 
Banchereau, J. and R. M. Steinman (1998). "Dendritic cells and the control of 
immunity." Nature 392(6673): 245-52. 
Barnden, M. J., J. Allison, et al. (1998). "Defective TCR expression in transgenic mice 
constructed using cDNA-based alpha- and beta-chain genes under the control of 
heterologous regulatory elements." Immunol Cell Biol 76(1): 34-40. 
Belghith, M., J. A. Bluestone, et al. (2003). "TGF-beta-dependent mechanisms mediate 
restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune 
diabetes." Nat Med 9(9): 1202-8. 
Bensinger, S. J., A. Bandeira, et al. (2001). "Major histocompatibility complex class II-
positive cortical epithelium mediates the selection of CD4(+)25(+) 
immunoregulatory T cells." J Exp Med 194(4): 427-38. 
Bevan, M. J. (1976). "Cross-priming for a secondary cytotoxic response to minor H 
antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay." 
J Exp Med 143(5): 1283-8. 
Bevan, M. J. (2006). "Cross-priming." Nat Immunol 7(4): 363-5. 
Blanas, E. and W. R. Heath (1999). "Oral administration of antigen can lead to the onset 
of autoimmune disease." Int Rev Immunol 18(3): 217-28. 
Brocker, T., M. Riedinger, et al. (1997). "Targeted expression of major histocompatibility 
complex (MHC) class II molecules demonstrates that dendritic cells can induce 
negative but not positive selection of thymocytes in vivo." J Exp Med 185(3): 541-
50. 
Buonocore, S., F. Paulart, et al. (2003). "Dendritic cells overexpressing CD95 (Fas) 
ligand elicit vigorous allospecific T-cell responses in vivo." Blood 101(4): 1469-
76. 
   
 86 
Buonocore, S., S. Van Meirvenne, et al. (2002). "Dendritic cells transduced with viral 
interleukin 10 or Fas ligand: no evidence for induction of allotolerance in vivo." 
Transplantation 73(1 Suppl): S27-30. 
Cavazzana-Calvo, M., S. Hacein-Bey, et al. (2000). "Gene therapy of human severe 
combined immunodeficiency (SCID)-X1 disease." Science 288(5466): 669-72. 
Chatenoud, L. (2003). "CD3 antibody treatment stimulates the functional capability of 
regulatory T cells." Novartis Found Symp 252: 279-86; discussion 286-90. 
Chatenoud, L. (2006). "Immune therapies of autoimmune diseases: are we approaching 
a real cure?" Curr Opin Immunol 18(6): 710-7. 
Check, E. (2005). "Gene therapy put on hold as third child develops cancer." Nature 
433(7026): 561. 
Chen, W., W. Jin, et al. (2003). "Conversion of peripheral CD4+CD25- naive T cells to 
CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor 
Foxp3." J Exp Med 198(12): 1875-86. 
Choy, E. H., A. Schantz, et al. (1998). "The pharmacokinetics and human anti-mouse 
antibody response in rheumatoid arthritis patients treated with a chimeric anti-
CD4 monoclonal antibody." Br J Rheumatol 37(7): 801-2. 
Cohen, Y. and A. Nagler (2004). "Treatment of refractory autoimmune diseases with 
ablative immunotherapy." Autoimmun Rev 3(2): 21-9. 
Coles, R. M., S. N. Mueller, et al. (2002). "Progression of armed CTL from draining 
lymph node to spleen shortly after localized infection with herpes simplex virus 
1." J Immunol 168(2): 834-8. 
Corcoran, L., I. Ferrero, et al. (2003). "The lymphoid past of mouse plasmacytoid cells 
and thymic dendritic cells." J Immunol 170(10): 4926-32. 
den Haan, J. M., S. M. Lehar, et al. (2000). "CD8(+) but not CD8(-) dendritic cells cross-
prime cytotoxic T cells in vivo." J Exp Med 192(12): 1685-96. 
Derbinski, J., A. Schulte, et al. (2001). "Promiscuous gene expression in medullary 
thymic epithelial cells mirrors the peripheral self." Nat Immunol 2(11): 1032-9. 
Dhodapkar, M. V. and R. M. Steinman (2002). "Antigen-bearing immature dendritic cells 
induce peptide-specific CD8(+) regulatory T cells in vivo in humans." Blood 
100(1): 174-7. 
   
 87 
Dhodapkar, M. V., R. M. Steinman, et al. (2001). "Antigen-specific inhibition of effector T 
cell function in humans after injection of immature dendritic cells." J Exp Med 
193(2): 233-8. 
Diebold, S. S., M. Cotten, et al. (2001). "MHC class II presentation of endogenously 
expressed antigens by transfected dendritic cells." Gene Ther 8(6): 487-93. 
Donello, J. E., J. E. Loeb, et al. (1998). "Woodchuck hepatitis virus contains a tripartite 
posttranscriptional regulatory element." J Virol 72(6): 5085-92. 
Eleveld-Trancikova, D., V. Triantis, et al. (2005). "The dendritic cell-derived protein DC-
STAMP is highly conserved and localizes to the endoplasmic reticulum." J 
Leukoc Biol 77(3): 337-43. 
Fearon, D. T. and R. M. Locksley (1996). "The instructive role of innate immunity in the 
acquired immune response." Science 272(5258): 50-3. 
Feldmann, M. (2002). "Development of anti-TNF therapy for rheumatoid arthritis." Nat 
Rev Immunol 2(5): 364-71. 
Fogg, D. K., C. Sibon, et al. (2006). "A clonogenic bone marrow progenitor specific for 
macrophages and dendritic cells." Science 311(5757): 83-7. 
Fong, L., D. Brockstedt, et al. (2001). "Dendritic cells injected via different routes induce 
immunity in cancer patients." J Immunol 166(6): 4254-9. 
Fontenot, J. D., M. A. Gavin, et al. (2003). "Foxp3 programs the development and 
function of CD4+CD25+ regulatory T cells." Nat Immunol 4(4): 330-6. 
Fontenot, J. D. and A. Y. Rudensky (2005). "A well adapted regulatory contrivance: 
regulatory T cell development and the forkhead family transcription factor 
Foxp3." Nat Immunol 6(4): 331-7. 
Gallegos, A. M. and M. J. Bevan (2004). "Central tolerance to tissue-specific antigens 
mediated by direct and indirect antigen presentation." J Exp Med 200(8): 1039-
49. 
Gaspar, H. B., K. L. Parsley, et al. (2004). "Gene therapy of X-linked severe combined 
immunodeficiency by use of a pseudotyped gammaretroviral vector." Lancet 
364(9452): 2181-7. 
Gordon, S. and P. R. Taylor (2005). "Monocyte and macrophage heterogeneity." Nat 
Rev Immunol 5(12): 953-64. 
   
 88 
Grulich, A. E., M. T. van Leeuwen, et al. (2007). "Incidence of cancers in people with 
HIV/AIDS compared with immunosuppressed transplant recipients: a meta-
analysis." Lancet 370(9581): 59-67. 
Gunzer, M., C. Weishaupt, et al. (2004). "A spectrum of biophysical interaction modes 
between T cells and different antigen-presenting cells during priming in 3-D 
collagen and in vivo." Blood 104(9): 2801-9. 
Hacein-Bey-Abina, S., C. Von Kalle, et al. (2003). "LMO2-associated clonal T cell 
proliferation in two patients after gene therapy for SCID-X1." Science 302(5644): 
415-9. 
Hartgers, F. C., J. L. Vissers, et al. (2000). "DC-STAMP, a novel multimembrane-
spanning molecule preferentially expressed by dendritic cells." Eur J Immunol 
30(12): 3585-90. 
Hawiger, D., K. Inaba, et al. (2001). "Dendritic cells induce peripheral T cell 
unresponsiveness under steady state conditions in vivo." J Exp Med 194(6): 769-
79. 
Heath, W. R., G. T. Belz, et al. (2004). "Cross-presentation, dendritic cell subsets, and 
the generation of immunity to cellular antigens." Immunol Rev 199: 9-26. 
Herold, K. C., W. Hagopian, et al. (2002). "Anti-CD3 monoclonal antibody in new-onset 
type 1 diabetes mellitus." N Engl J Med 346(22): 1692-8. 
Hogquist, K. A., S. C. Jameson, et al. (1994). "T cell receptor antagonist peptides 
induce positive selection." Cell 76(1): 17-27. 
Huang, X., S. Cho, et al. (2007). "Hematopoietic stem cells: generation and self-
renewal." Cell Death Differ 14(11): 1851-9. 
Huang, Y. M., J. S. Yang, et al. (2000). "Autoantigen-pulsed dendritic cells induce 
tolerance to experimental allergic encephalomyelitis (EAE) in Lewis rats." Clin 
Exp Immunol 122(3): 437-44. 
Hugues, S., L. Fetler, et al. (2004). "Distinct T cell dynamics in lymph nodes during the 
induction of tolerance and immunity." Nat Immunol 5(12): 1235-42. 
Iwasaki, H. and K. Akashi (2007). "Myeloid lineage commitment from the hematopoietic 
stem cell." Immunity 26(6): 726-40. 
Kamath, A. T., S. Henri, et al. (2002). "Developmental kinetics and lifespan of dendritic 
cells in mouse lymphoid organs." Blood 100(5): 1734-41. 
   
 89 
Kang, E. S. and J. Iacomini (2002). "Induction of central deletional T cell tolerance by 
gene therapy." J Immunol 169(4): 1930-5. 
Kang, Y., M. Melo, et al. (1999). "Induction of hyporesponsiveness to intact foreign 
protein via retroviral-mediated gene expression: the IgG scaffold is important for 
induction and maintenance of immune hyporesponsiveness." Proc Natl Acad Sci 
U S A 96(15): 8609-14. 
Keating, M. J., I. Flinn, et al. (2002). "Therapeutic role of alemtuzumab (Campath-1H) in 
patients who have failed fludarabine: results of a large international study." Blood 
99(10): 3554-61. 
Khattri, R., T. Cox, et al. (2003). "An essential role for Scurfin in CD4+CD25+ T 
regulatory cells." Nat Immunol 4(4): 337-42. 
Kiel, M. J., O. H. Yilmaz, et al. (2005). "SLAM family receptors distinguish hematopoietic 
stem and progenitor cells and reveal endothelial niches for stem cells." Cell 
121(7): 1109-21. 
Kim, S. H., S. Kim, et al. (2001). "Effective treatment of established murine collagen-
induced arthritis by systemic administration of dendritic cells genetically modified 
to express IL-4." J Immunol 166(5): 3499-505. 
Kirk, A. D., L. C. Burkly, et al. (1999). "Treatment with humanized monoclonal antibody 
against CD154 prevents acute renal allograft rejection in nonhuman primates." 
Nat Med 5(6): 686-93. 
Kirk, A. D., D. M. Harlan, et al. (1997). "CTLA4-Ig and anti-CD40 ligand prevent renal 
allograft rejection in primates." Proc Natl Acad Sci U S A 94(16): 8789-94. 
Kosaka, H. and J. Sprent (1993). "Tolerance of CD8+ T cells developing in parent-->F1 
chimeras prepared with supralethal irradiation: step-wise induction of tolerance in 
the intrathymic and extrathymic environments." J Exp Med 177(2): 367-78. 
Kraunus, J., D. H. Schaumann, et al. (2004). "Self-inactivating retroviral vectors with 
improved RNA processing." Gene Ther 11(21): 1568-78. 
Kukita, T., N. Wada, et al. (2004). "RANKL-induced DC-STAMP is essential for 
osteoclastogenesis." J Exp Med 200(7): 941-6. 
Kurts, C., R. M. Sutherland, et al. (1999). "CD8 T cell ignorance or tolerance to islet 
antigens depends on antigen dose." Proc Natl Acad Sci U S A 96(22): 12703-7. 
   
 90 
Larsen, C. P., E. T. Elwood, et al. (1996). "Long-term acceptance of skin and cardiac 
allografts after blocking CD40 and CD28 pathways." Nature 381(6581): 434-8. 
Lauterbach, H., K. M. Kerksiek, et al. (2004). "Protection from bacterial infection by a 
single vaccination with replication-deficient mutant herpes simplex virus type 1." 
J Virol 78(8): 4020-8. 
Li, Z., U. Modlich, et al. (2004). "Safety and efficacy in retrovirally modified 
haematopoietic cell therapy." Best Pract Res Clin Haematol 17(3): 493-503. 
Liu, Y. J. (2005). "IPC: professional type 1 interferon-producing cells and plasmacytoid 
dendritic cell precursors." Annu Rev Immunol 23: 275-306. 
Lois, C., E. J. Hong, et al. (2002). "Germline transmission and tissue-specific 
expression of transgenes delivered by lentiviral vectors." Science 295(5556): 
868-72. 
Ludewig, B., B. Odermatt, et al. (1998). "Dendritic cells induce autoimmune diabetes 
and maintain disease via de novo formation of local lymphoid tissue." J Exp Med 
188(8): 1493-501. 
MacDonald, K. P., V. Rowe, et al. (2005). "Cytokine expanded myeloid precursors 
function as regulatory antigen-presenting cells and promote tolerance through IL-
10-producing regulatory T cells." J Immunol 174(4): 1841-50. 
Marshall, E. (2003). "Gene therapy. Second child in French trial is found to have 
leukemia." Science 299(5605): 320. 
Mathis, D. and C. Benoist (2004). "Back to central tolerance." Immunity 20(5): 509-16. 
Miller, G., S. Lahrs, et al. (2002). "Adenovirus infection enhances dendritic cell 
immunostimulatory properties and induces natural killer and T-cell-mediated 
tumor protection." Cancer Res 62(18): 5260-6. 
Min, W. P., R. Gorczynski, et al. (2000). "Dendritic cells genetically engineered to 
express Fas ligand induce donor-specific hyporesponsiveness and prolong 
allograft survival." J Immunol 164(1): 161-7. 
Modigliani, Y., V. Thomas-Vaslin, et al. (1995). "Lymphocytes selected in allogeneic 
thymic epithelium mediate dominant tolerance toward tissue grafts of the thymic 
epithelium haplotype." Proc Natl Acad Sci U S A 92(16): 7555-9. 
Moreland, L. W., P. W. Pratt, et al. (1995). "Double-blind, placebo-controlled multicenter 
trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid 
   
 91 
arthritis patients receiving concomitant methotrexate." Arthritis Rheum 38(11): 
1581-8. 
Munn, D. H., M. D. Sharma, et al. (2004). "Expression of indoleamine 2,3-dioxygenase 
by plasmacytoid dendritic cells in tumor-draining lymph nodes." J Clin Invest 
114(2): 280-90. 
Nakajima, A. (2006). "Application of cellular gene therapy for rheumatoid arthritis." Mod 
Rheumatol 16(5): 269-75. 
Okada, T., Z. X. Lian, et al. (2003). "Murine thymic plasmacytoid dendritic cells." Eur J 
Immunol 33(4): 1012-9. 
Papaccio, G., F. Nicoletti, et al. (2000). "Prevention of spontaneous autoimmune 
diabetes in NOD mice by transferring in vitro antigen-pulsed syngeneic dendritic 
cells." Endocrinology 141(4): 1500-5. 
Pooley, J. L., W. R. Heath, et al. (2001). "Cutting edge: intravenous soluble antigen is 
presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T 
cells by CD8+ dendritic cells." J Immunol 166(9): 5327-30. 
Probst, H. C., J. Lagnel, et al. (2003). "Inducible transgenic mice reveal resting dendritic 
cells as potent inducers of CD8+ T cell tolerance." Immunity 18(5): 713-20. 
Probst, H. C., K. McCoy, et al. (2005). "Resting dendritic cells induce peripheral CD8+ T 
cell tolerance through PD-1 and CTLA-4." Nat Immunol 6(3): 280-6. 
Ramsdell, F. and B. J. Fowlkes (1990). "Clonal deletion versus clonal anergy: the role of 
the thymus in inducing self tolerance." Science 248(4961): 1342-8. 
Ramsey, C., O. Winqvist, et al. (2002). "Aire deficient mice develop multiple features of 
APECED phenotype and show altered immune response." Hum Mol Genet 
11(4): 397-409. 
Redmond, W. L. and L. A. Sherman (2005). "Peripheral tolerance of CD8 T 
lymphocytes." Immunity 22: 275-284. 
Reis e Sousa, C. (2006). "Dendritic cells in a mature age." Nat Rev Immunol 6(6): 476-
83. 
Riviere, I., K. Brose, et al. (1995). "Effects of retroviral vector design on expression of 
human adenosine deaminase in murine bone marrow transplant recipients 
engrafted with genetically modified cells." Proc Natl Acad Sci U S A 92(15): 
6733-7. 
   
 92 
Robertson, J. M., P. E. Jensen, et al. (2000). "DO11.10 and OT-II T cells recognize a C-
terminal ovalbumin 323-339 epitope." J Immunol 164(9): 4706-12. 
Ross, R., S. Sudowe, et al. (2003). "Transcriptional targeting of dendritic cells for gene 
therapy using the promoter of the cytoskeletal protein fascin." Gene Ther 10(12): 
1035-40. 
Sakaguchi, S. (2004). "Naturally arising CD4+ regulatory t cells for immunologic self-
tolerance and negative control of immune responses." Annu Rev Immunol 22: 
531-62. 
Sakaguchi, S., K. Fukuma, et al. (1985). "Organ-specific autoimmune diseases induced 
in mice by elimination of T cell subset. I. Evidence for the active participation of T 
cells in natural self-tolerance; deficit of a T cell subset as a possible cause of 
autoimmune disease." J Exp Med 161(1): 72-87. 
Sapoznikov, A., J. A. Fischer, et al. (2007). "Organ-dependent in vivo priming of naive 
CD4+,but not CD8+,T cells by plasmacytoid dendritic cells." J Exp Med 204(8): 
1923-33. 
Schuler, G., B. Schuler-Thurner, et al. (2003). "The use of dendritic cells in cancer 
immunotherapy." Curr Opin Immunol 15(2): 138-47. 
Schulze-Koops, H. and P. E. Lipsky (2000). "Anti-CD4 monoclonal antibody therapy in 
human autoimmune diseases." Curr Dir Autoimmun 2: 24-49. 
Shevach, E. M. (2002). "CD4+ CD25+ suppressor T cells: more questions than 
answers." Nat Rev Immunol 2(6): 389-400. 
Shigematsu, H., B. Reizis, et al. (2004). "Plasmacytoid dendritic cells activate lymphoid-
specific genetic programs irrespective of their cellular origin." Immunity 21(1): 43-
53. 
Shortman, K. and S. H. Naik (2007). "Steady-state and inflammatory dendritic-cell 
development." Nat Rev Immunol 7(1): 19-30. 
Siegel, R. M., F. K. Chan, et al. (2000). "The multifaceted role of Fas signaling in 
immune cell homeostasis and autoimmunity." Nat Immunol 1(6): 469-74. 
Soriano, P., G. Friedrich, et al. (1991). "Promoter interactions in retrovirus vectors 
introduced into fibroblasts and embryonic stem cells." J Virol 65(5): 2314-9. 
   
 93 
Sporri, R. and C. Reis e Sousa (2005). "Inflammatory mediators are insufficient for full 
dendritic cell activation and promote expansion of CD4+ T cell populations 
lacking helper function." Nat Immunol 6(2): 163-70. 
Sprangers, B., B. Van Wijmeersch, et al. (2007). "Experimental and clinical approaches 
for optimization of the graft-versus-leukemia effect." Nat Clin Pract Oncol 4(7): 
404-14. 
Sprent, J., H. Kosaka, et al. (1993). "Intrathymic and extrathymic tolerance in bone 
marrow chimeras." Immunol Rev 133: 151-76. 
Starr, T. K., S. C. Jameson, et al. (2003). "Positive and negative selection of T cells." 
Annu Rev Immunol 21: 139-76. 
Steinman, R. M., D. Hawiger, et al. (2003). "Tolerogenic dendritic cells." Annu Rev 
Immunol 21: 685-711. 
Takayama, T., A. E. Morelli, et al. (2000). "Feasibility of CTLA4Ig gene delivery and 
expression in vivo using retrovirally transduced myeloid dendritic cells that 
induce alloantigen-specific T cell anergy in vitro." Gene Ther 7(15): 1265-73. 
Takayama, T., Y. Nishioka, et al. (1998). "Retroviral delivery of viral interleukin-10 into 
myeloid dendritic cells markedly inhibits their allostimulatory activity and 
promotes the induction of T-cell hyporesponsiveness." Transplantation 66(12): 
1567-74. 
Teitell, M. A. and H. K. Mikkola (2006). "Transcriptional activators, repressors, and 
epigenetic modifiers controlling hematopoietic stem cell development." Pediatr 
Res 59(4 Pt 2): 33R-9R. 
Thanos, D. and T. Maniatis (1995). "Virus induction of human IFN beta gene expression 
requires the assembly of an enhanceosome." Cell 83(7): 1091-100. 
Tian, C., J. Bagley, et al. (2003). "Induction of T cell tolerance to a protein expressed in 
the cytoplasm through retroviral-mediated gene transfer." J Gene Med 5(5): 359-
65. 
Trucco, M. (2005). "Regeneration of the pancreatic beta cell." J Clin Invest 115(1): 5-12. 
Tsokos, G. C. and G. T. Nepom (2000). "Gene therapy in the treatment of autoimmune 
diseases." J Clin Invest 106(2): 181-3. 
van der Meide, P. H., M. C. de Labie, et al. (1998). "Discontinuation of treatment with 
IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in 
   
 94 
Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and 
excessive expansion of autoreactive T cells as disease promoting mechanisms." 
J Neuroimmunol 84(1): 14-23. 
Vignery, A. (2005). "Macrophage fusion: the making of osteoclasts and giant cells." J 
Exp Med 202(3): 337-40. 
Vile, R. G., R. M. Diaz, et al. (1995). "Tissue-specific gene expression from Mo-MLV 
retroviral vectors with hybrid LTRs containing the murine tyrosinase 
enhancer/promoter." Virology 214(1): 307-13. 
Villadangos, J. A. and P. Schnorrer (2007). "Intrinsic and cooperative antigen-
presenting functions of dendritic-cell subsets in vivo." Nat Rev Immunol 7(7): 
543-55. 
von Boehmer, H. (1994). "Positive selection of lymphocytes." Cell 76(2): 219-28. 
Vremec, D., J. Pooley, et al. (2000). "CD4 and CD8 expression by dendritic cell 
subtypes in mouse thymus and spleen." J Immunol 164(6): 2978-86. 
Walker, L. S. and A. K. Abbas (2002). "The enemy within: keeping self-reactive T cells 
at bay in the periphery." Nat Rev Immunol 2(1): 11-9. 
Watanabe, N., Y. H. Wang, et al. (2005). "Hassall's corpuscles instruct dendritic cells to 
induce CD4+CD25+ regulatory T cells in human thymus." Nature 436(7054): 
1181-5. 
Weir, C. R., K. Nicolson, et al. (2002). "Experimental autoimmune encephalomyelitis 
induction in naive mice by dendritic cells presenting a self-peptide." Immunol Cell 
Biol 80(1): 14-20. 
Werner-Klein, M., C. Dresch, et al. (2007). "Transcriptional targeting of B cells for 
induction of peripheral CD8 T cell tolerance." J Immunol 178(12): 7738-46. 
Werner, M., J. Kraunus, et al. (2004). "B-cell-specific transgene expression using a self-
inactivating retroviral vector with human CD19 promoter and viral post-
transcriptional regulatory element." Gene Ther 11(12): 992-1000. 
Werner, T. (1999). "Models for prediction and recognition of eukaryotic promoters." 
Mamm Genome 10(2): 168-75. 
Wilson, A., G. M. Oser, et al. (2007). "Dormant and self-renewing hematopoietic stem 
cells and their niches." Ann N Y Acad Sci. 
   
 95 
Wilson, N. S., D. El-Sukkari, et al. (2003). "Most lymphoid organ dendritic cell types are 
phenotypically and functionally immature." Blood 102(6): 2187-94. 
Woods, N. B., V. Bottero, et al. (2006). "Gene therapy: therapeutic gene causing 
lymphoma." Nature 440(7088): 1123. 
Wu, L., D. Vremec, et al. (1995). "Mouse thymus dendritic cells: kinetics of development 
and changes in surface markers during maturation." Eur J Immunol 25(2): 418-
25. 
Yagi, M., T. Miyamoto, et al. (2005). "DC-STAMP is essential for cell-cell fusion in 
osteoclasts and foreign body giant cells." J Exp Med 202(3): 345-51. 
Yee, J. K., J. C. Moores, et al. (1987). "Gene expression from transcriptionally disabled 
retroviral vectors." Proc Natl Acad Sci U S A 84(15): 5197-201. 
Zufferey, R., T. Dull, et al. (1998). "Self-inactivating lentivirus vector for safe and 
efficient in vivo gene delivery." J Virol 72(12): 9873-80. 
 
   
 96 
9. Curriculum Vitae 
 
PERSONAL DATA: 
 
NAME: Christiane Dresch 
BIRTH: September 12th, 1975, Campo Bom, Brazil 
LANGUAGES: Portuguese, English and German 
ADDRESS: 
 Private Wingert, 1 
  8466 Trüllikon, Switzerland 
  phone: +41 (0) 763 60 1209 
 
 Work University of Zurich, Institute of Virology 
Winterthurerstr. 266a 
  8057 Zurich, Switzerland 
  phone: +41 (0) 44 6358 707 
  cdresch@vetvir.unizh.ch 
 
UNDERGRADUATE STUDIES:  
B.Sc. Pharmaceutical Sciences – “Universidade Federal do Rio Grande do Sul- 
UFRGS” (1994- 2000).  
 
GRADUATE STUDIES:  
M. Sc. Program in Genetics and Molecular Biology- Genetics Institute, Immunogenetics 
Laboratory, UFRGS (March 2001 – May 2002). 
 
Ph.D. Institute of Immunology, Ludwig-Maximilians-University, Munich (April 2003-
December 2007). 
 
PUBLISHED PAPERS: 
 
DRESCH C, EDELMANN SL, MARCONI P, BROCKER T. Lentiviral-mediated 
transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo, J 
Immunol. 181(7):4495-06, 2008. 
   
 97 
 
 
WERNER-KLEIN M, DRESCH C, MARCONI P, BROCKER T. Transcriptional targeting 
of B cells for induction of peripheral CD8 T cell tolerance. J Immunol. Jun 
15;178(12):7738-46, 2007. 
 
CHIES JA, DRESCH C, CRUZ MS, DA SILVA G, BARROS E, BITTAR C, 
FRIEDRISCH J, SILLA LM. Immunosuppressive therapy for kidney transplant prevents 
vaso-occlusive crisis in a haemoglobin SC disease patient. Med 
Hypotheses.;64(1):174-6, 2005. 
 
DRESCH, C.; XAVIER, R.; BRENOL, J.C.; NARDI, N.B. E CHIES, J.A.B. 
Analysis of two T Cell Receptor BV Gene Segment Polymorphisms in Caucasoid 
Brazilian Patients with Rheumatoid Arthritis. Immunology Letters  Dec 15;90(2-3):77-
80, 2003. 
 
DRESCH, C.; NARDI, N.B. AND CHIES, J.A.B. TCRBV3S1 and TCRBV18 gene 
segment polymorphisms in Brazilian Caucasoid and Black populations. European 
Journal of Immunogenetics, 29(1):11-15, 2002 
 
DRESCH, C.; MARASCA, J.A.; CANABARRO, U.; XAVIER, R.; BRENOL, J.C. E 
CHIES, J.A.B. T lynphocytes, T cell receptor (TVR) gene rearrangement and usage of 
TCR polymorphism as markers in rheumatoid arthritis. Revista Brasileira de 
Reumatologia, 41(1): 21-26, 2001. 
 
 
Participation in Congresses during the Ph.D. studies:  
 
DRESCH C AND BROCKER T. (2007), Antigen-specific tolerance induction by 
transcriptional targeting of dendritic cells with lentiviral vector, 10th Annual Meeting of 
the American Society of Gene Therapy . Seattle, USA 
 
DRESCH C AND BROCKER T. (2007), Antigen-specific tolerance induction by 
transcriptional targeting of dendritic cells with lentiviral vector, Rolduc Workshop on T 
cell Biology. Krekade, Netherlands 
 
DRESCH C AND BROCKER T. (2006), Antigen-specific tolerance induction by 
transcriptional targeting of dendritic cells with lentiviral vector. 16th European 
Congress of Immunology, Paris, France 
 
DRESCH C AND BROCKER T. (2006), Antigen-specific tolerance induction by 
transcriptional targeting of dendritic cells with lentiviral vector 9th International 
Conference on Dendritic Cells, Edinburgh, Schotland. 
 
   
 98 
10. Acknowledgements 
 
 I want to thank Prof. Dr. Thomas Brocker for the opportunity to perform my Ph.D. 
under his supervision. I am also very grateful for all the freedom that I had during my 
work. 
 
 
 I want to thank all my lab colleagues for the collaborative atmosphere. I am 
especially grateful To Melanie Werner-Klein for her technical and scientific support in 
the beginning of my Ph.D. studies; Jana Körner for her technical assistance and 
constant good mood; Stephanie Bayerlein for her friendship and good atmosphere 
during the period in which we shared “our space”; and Nancy Luckashenak for her 
friendship and support in the last months of my PhD and for reviewing this manuscript.  
 
 
 I want to thank Jeferson for his support, stimuli and friendship during all my Ph.D. 
study. 
 
 
 I want to thank especially my parents and my brother for their permanent 
incentive, encouragement and affection. 
 
 
 To my special “queridos” friends that even when not being close to me physically, 
were always supporting me and never letting me feel alone.  
 
 
 To CAPES, related to the Brazilian Ministry of Education, for providing me a 
scholarship during the first three years of my Ph.D. study. 
 
 
 
